Methicillin-resistant Staphylococcus aureus in Finland : recent changes in the epidemiology, long-term facility aspects, and phenotypic and molecular detection of isolates by Kerttula, Anne-Marie
Publications of the National Public Health Institute   A   16/2007
Department of Bacterial and Inﬂ ammatory Diseases 
National Public Health Institute Helsinki, Finland
and
Faculty of Biosciences,
University of Helsinki,
Finland
Methicillin-resistant Staphylococcus 
aureus in Finland: recent changes in 
the epidemiology, long-term facility
aspects, and phenotypic and mole-
cular detection of isolates
Anne-Marie Kerttula
Long-term facility
10
0
8060 10
0
8060
 
 
 
 
 
Methicillin-resistant Staphylococcus aureus in Finland: 
recent changes in the epidemiology, long-term facility 
aspects, and phenotypic and molecular detection of 
isolates 
 
Anne-Marie Kerttula 
 
 
 
 
 
 
ACADEMIC DISSERTATION 
 
To be presented with the permission of the Faculty of Biosciences, University of Helsinki,  
for public examination in the Auditorium XII, University Main Building, Unioninkatu 34,  
on November 30th 2007, at 12.00 noon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Department of Bacterial and Inflammatory Diseases, 
National Public Health Institute, 
Helsinki, Finland  
and 
Faculty of Biosciences, 
University of Helsinki, 
Helsinki, Finland 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publications of the National Public Health Institutes KTL A16 / 2007 
 
Copyright National Public Health Institute 
 
Julkaisija-Utgivare-Publisher 
 
Kansanterveyslaitos (KTL) 
Mannerheimintie 166 
00300 Helsinki 
Puh. vaihde (09) 474 41, telefax (09) 4744 8408 
 
Folkhälsoinstitutet 
Mannerheimvägen 166 
00300 Helsingfors 
Tel. växel (09) 474 41, telefax (09) 4744 8408 
 
National Public Health Institute 
Mannerheimintie 166 
FIN-00300 Helsinki, Finland 
Telephone +358 9 474 41, telefax +358 9 4744 8408 
 
ISBN 978-951-740-742-7 (print) 
ISSN 0359-3584 (print) 
ISBN 978-951-740-743-4 (pdf) 
ISSN 1458-6290 (pdf) 
 
Edita Prima Oy 
Helsinki 2007 
Supervised by 
 
Docent Jaana Vuopio-Varkila, MD, PhD 
Department of Bacterial and Inflammatory Diseases 
National Public Health Institute (KTL), Helsinki, Finland 
 
Docent Outi Lyytikäinen, MD, PhD 
Department of Infectious Disease Epidemiology 
National Public Health Institute (KTL), Helsinki, Finland 
 
Reviewed by 
 
Docent Olli Meurman, MD, PhD 
Clinical Microbiology Laboratory, TYKSLAB 
Turku University Hospital, Turku, Finland 
 
Docent Markku Koskela, MD, PhD 
Clinical Microbiology Laboratory 
Oulu University Hospital, Oulu, Finland 
 
Opponent 
 
Docent Risto Vuento, MD, PhD 
Centre for Laboratory Medicine 
Tampere University Hospital, Tampere, Finland 
 
Anne-Marie Kerttula, Methicillin-resistant Staphylococcus aureus in Finland: recent changes in the epidemiology, long-
term facility aspects, and phenotypic and molecular detection of isolates 
Publications of the National Public Health Institute, A16/2007, 91 pages 
ISBN 978-951-740-742-7; 978-951-740-743-4 (pdf-version); ISSN 0359-3584 (print); 1458-6290 (pdf-version) 
http://www.ktl.fi/portal/4043  
 
ABSTRACT 
 
Staphylococcus aureus is one of the most important bacteria that cause disease in humans, and 
methicillin-resistant S. aureus (MRSA) has become the most commonly identified antibiotic-
resistant pathogen in many parts of the world. MRSA rates have been stable for many years in the 
Nordic countries and the Netherlands with a low MRSA prevalence in Europe, but in the recent 
decades, MRSA rates have increased in those low-prevalence countries as well. MRSA has been 
established as a major hospital pathogen, but has also been found increasingly in long-term facilities 
(LTF) and in communities of persons with no connections to the health-care setting. In Finland, the 
annual number of MRSA isolates reported to the National Infectious Disease Register (NIDR) has 
constantly increased, especially outside the Helsinki metropolitan area. Molecular typing has 
revealed numerous outbreak strains of MRSA, some of which have previously been associated with 
community acquisition.  
 
In this work, data on MRSA cases notified to the NIDR and on MRSA strain types identified with 
pulsed-field gel electrophoresis (PFGE), multilocus sequence typing (MLST), and staphylococcal 
cassette chromosome mec (SCCmec) typing at the National Reference Laboratory (NRL) in Finland 
from 1997 to 2004 were analyzed. An increasing trend in MRSA incidence in Finland from 1997 to 
2004 was shown. In addition, non-multi-drug resistant (NMDR) MRSA isolates, especially those 
resistant only to methicillin/oxacillin, showed an emerging trend. The predominant MRSA strains 
changed over time and place, but two internationally spread epidemic strains of MRSA, FIN-16 and 
FIN-21, were related to the increase detected most recently. Those strains were also one cause of 
the strikingly increasing invasive MRSA findings. The rise of MRSA strains with SCCmec types IV 
or V, possible community-acquired MRSA was also detected.  
 
With questionnaires, the diagnostic methods used for MRSA identification in Finnish microbiology 
laboratories and the number of MRSA screening specimens studied were reviewed. Surveys, which 
focused on the MRSA situation in long-term facilities in 2001 and on the background information 
of MRSA-positive persons in 2001-2003, were also carried out. The rates of MRSA and screening 
practices varied widely across geographic regions. Part of the NMDR MRSA strains could remain 
undetected in some laboratories because of insufficient diagnostic techniques used. The increasing 
proportion of elderly population carrying MRSA suggests that MRSA is an emerging problem in 
Finnish long-term facilities. Among the patients, 50% of the specimens were taken on a clinical 
basis, 43% on a screening basis after exposure to MRSA, 3% on a screening basis because of 
hospital contact abroad, and 4% for other reasons. 
 
In response to an outbreak of MRSA possessing a new genotype that occurred in a health care ward 
and in an associated nursing home of a small municipality in Northern Finland in autumn 2003, a 
point-prevalence survey was performed six months later. In the same study, the molecular 
epidemiology of MRSA and methicillin-sensitive S. aureus (MSSA) strains were also assessed, the 
results to the national strain collection compared, and the difficulties of MRSA screening with low-
level oxacillin-resistant isolates encountered. The original MRSA outbreak in LTF, which consisted 
of isolates possessing a nationally new PFGE profile (FIN-22) and internationally rare MLST type 
(ST-27), was confined. Another previously unrecognized MRSA strain was found with additional 
screening, possibly indicating that current routine MRSA screening methods may be insufficiently 
sensitive for strains possessing low-level oxacillin resistance. Most of the MSSA strains found were 
genotypically related to the epidemic MRSA strains, but only a few of them had received the 
SCCmec element, and all those strains possessed the new SCCmec type V.  
 
In the second largest nursing home in Finland, the colonization of S. aureus and MRSA, and the 
role of screening sites along with broth enrichment culture on the sensitivity to detect S. aureus 
were studied. Combining the use of enrichment broth and perineal swabbing, in addition to nostrils 
and skin lesions swabbing, may be an alternative for throat swabs in the nursing home setting, 
especially when residents are uncooperative.  
 
Finally, in order to evaluate adequate phenotypic and genotypic methods needed for reliable 
laboratory diagnostics of MRSA, oxacillin disk diffusion and MIC tests to the cefoxitin disk 
diffusion method at both +35°C and +30°C, both with or without an addition of sodium chloride 
(NaCl) to the Müller Hinton test medium, and in-house PCR to two commercial molecular methods 
(the GenoType® MRSA test and the EVIGENETM MRSA Detection test) with different bacterial 
species in addition to S. aureus were compared. The cefoxitin disk diffusion method was superior to 
that of oxacillin disk diffusion and to the MIC tests in predicting mecA-mediated resistance in S. 
aureus when incubating at +35°C with or without the addition of NaCl to the test medium. Both the 
Geno Type® MRSA and EVIGENETM MRSA Detection tests are usable, accurate, cost-effective, 
and sufficiently fast methods for rapid MRSA confirmation from a pure culture. 
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TIIVISTELMÄ 
 
Metisilliini-resistentistä Staphylococcus aureuksesta (MRSA) näyttää tulleen pysyvä 
maailmanlaajuinen ongelma. MRSA on yksi tärkeimmistä tautia aiheuttavista bakteereista ja siitä 
on tullut yleisin mikrobilääkkeille resistentti patogeeni monissa maissa. Pohjoismaissa ja 
Hollannissa MRSA-kantoja on pitkään eristetty vähäisiä, tasaisesti nousevia määriä, mutta viime 
vuosina myös näissä maissa MRSA-kannat ovat selkeästi lisääntyneet. MRSA on ollut jo kauan 
sairaaloiden vaivana, mutta nykyään sitä löydetään yhä useammin myös pitkäaikaislaitospotilailta 
sekä henkilöiltä, joilla ei tiedetä olleen yhteyttä terveydenhuollon laitoksiin. Molekyylibiologisten 
menetelmien avulla on tunnistettu useita MRSA-epidemioita, joista jotkut viittaavat mahdollisiin 
avohoitoperäisiin tartuntoihin. 
 
Suomessa Kansanterveyslaitoksen (KTL) tartuntatautirekisteriin (ttr) ilmoitettujen MRSA-kantojen 
lukumäärä on lisääntynyt selkeästi viime vuosina. Samaan aikaan myös kliinisen mikrobiologian 
laboratorioiden KTL:n referenssilaboratorioon lähettämien MRSA-kantojen määrä on noussut. 
Tässä väitöskirjassa tutkittiin MRSA:n muuttunutta epidemiologiaa analysoimalla ttr:n ilmoituksia 
sekä referenssilaboratorioon lähetettyjen kantojen ominaisuuksia Suomessa vuosina 1997-2004. 
Lisäksi arvioitiin MRSA-diagnostiikan tasoa kliinisen mikrobiologian laboratorioissa, 
sairaanhoitopiirien MRSA-seulonta-aktiviteettia, ja pitkäaikaishoitolaitosten MRSA-tilannetta 
vuonna 2001, sekä MRSA-positiivisten henkilöiden näytteenottoperustetta vuosina 2001-2003 
kyselytutkimusten avulla.  
 
Eri geenityypitysmenetelmien (PFGE, MLST, SCCmec) avulla KTL:n referenssilaboratoriossa 
todettiin, että vallitsevat MRSA-kannat ovat vaihdelleet vuosittain eri puolilla Suomea, mutta 
viimeaikaisen nousun takana oli kaksi kansainvälistä moniresistenttiä MRSA-epidemiakantaa. 
Nämä kaksi kantaa vallitsivat myös jyrkästi lisääntyneissä verilöydöksissä. Myös mahdollisten 
avohoidon MRSA-kantojen sekä vain beetalaktaameille resistenttien kantojen osuudet lisääntyivät. 
Kyselytutkimuksen perusteella voitaneen epäillä, että osa näistä vain beetalaktaameille resistenteistä 
kannoista on saattanut jäädä havaitsematta kliinisen mikrobiologian laboratorioiden riittämättömän 
MRSA-diagnostiikan vuoksi. Saman kyselyn perusteella voidaan todeta, että MRSA-löydösten 
määrä on vaihdellut sairaanhoitopiireittäin, mutta se ei ole korreloinut seulonta-aktiviteetin kanssa. 
Toisen kyselytutkimuksen perusteella voitiin todeta, että MRSA:n lisääntyminen vanhusväestössä 
viittaa sen aiheuttamaan lisääntyvään ongelmaan vanhainkodeissa. Kolmannesta 
kyselytutkimuksesta selvisi, että 50 % MRSA-positiivisten potilaiden seulontanäytteistä oli otettu 
kliinisillä perusteilla, 43 % MRSA-altistumiseen liittyvillä seulontaperusteilla, 3 % ulkomaan 
sairaalakontakteihin liittyvillä seulontaperusteilla, ja 4 % jonkin muun syyn takia.  
 
Pohjoissuomalaisessa pitkäaikaishoitolaitoksessa syksyllä 2003 tapahtuneen, perimältään 
omanlaisen ja selvästi rajatun MRSA-epidemian vuoksi haluttiin selvittää tarkemmin 
pitkäaikaishoitolaitoksen MRSA:n epidemiologiaa, sekä tehdä asukkaista uusi MRSA-seulonta 
helmikuussa 2004. Lisäksi analysoitiin asukkaiden MRSA- sekä metisilliinille/oksasilliinille 
herkkien S. aureusten (MSSA)-löydösten perimää vertaamalla niitä kansalliseen MRSA-
kantakokoelmaan.  Uudessa seulonnassa löytyi alkuperäisen MRSA-epidemiakannan lisäksi toinen, 
Suomesta aiemmin kuvattu MRSA-epidemiakanta. Tämä kanta ei ole mahdollisesti tullut esille 
laitoksessa tapahtuneissa aikaisemmissa seulonnoissa, koska kannan alhainen resistenssi 
metisilliinille/oksasilliinille voi haitata sen löytymistä tavallisella MRSA-seulontamaljalla. 
Perimäanalyysin perusteella todettiin, että MRSA ja MSSA-kantojen perimä voi olla samanlainen, 
mutta vain osa MSSA-kannoista on saanut metisilliiniresistenssiä aiheuttavan SCCmec-elementin. 
Tässä tapauksessa kaikilla laitoksesta löytyneillä MRSA-kannoilla oli sama SCCmec-tyyppi V 
kantojen perimästä riippumatta.  
 
Suomen toiseksi suurimmassa vanhainkodissa tutkittiin asukkaiden MSSA- sekä MRSA-
kantajuutta. Lisäksi arvioitiin, miten eri näytteenottopaikkojen määrä ja rikastusviljelyn käyttö 
vaikuttavat S. aureuksen (MRSA ja MSSA) löytymiseen. Todettiin, että perineum-näytteiden otto 
sekä rikasteviljelyn käyttö yhdistettynä nenä- ja haavanäytteiden ottoon voisi olla vaihtoehto 
nielunäytteiden otolle. Tämä toimisi etenkin asukkailla, joilta näytteenotto ei suju yhteistyökyvyn 
puutteen vuoksi. 
 
Lopuksi arvioitiin feno- ja genotyyppisiä menetelmiä, jotka olisivat tarkoituksenmukaisia MRSA:n 
tunnistamisessa kliinisen mikrobiologian laboratorioissa. S. aureus-kantojen 
metisilliini/oksasilliiniherkkyyttä tutkittiin oksasilliini-kiekkotestillä ja -MIC-menetelmällä, sekä 
kefoksitiini-kiekkotestillä. Menetelmät tehtiin +35°C:ssa ja +30°C:ssa Müller-Hinton agarilla, 
natriumkloridilisällä tai ilman sitä. Lisäksi verrattiin KTL:n referenssilaboratoriossa käytössä olevaa 
perinteistä mecA-nuc-PCR-menetelmää kaupallisiin GenoType® MRSA- sekä EVIGENETM MRSA 
Detection-testeihin. Todettiin, että kefoksitiini-kiekkotesti oli ylivertainen ennustamaan S. 
aureuksen metisilliini/oksasilliiniresistenssiä ja että molemmat kaupalliset genotyyppiset 
menetelmät olivat käyttökelpoisia, tarkkoja, hinta-laatusuhteeltaan sopivia, sekä riittävän nopeita 
menetelmiä MRSA:n tunnistamiseen puhdasviljelystä.  
 
 
 
Avainsanat: metisilliini-resistentti Staphylococcus aureus, MRSA, oksasilliini, kefoksitiini, 
epidemiologia, pitkäaikaishoitolaitos, tyypitysmenetelmä 
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3ABBREVIATIONS 
agr accessory gene regulator 
aux auxillary factors for methicillin resistance 
BORSA borderline-resistant Staphylococcus aureus 
BURST Based Upon Related Sequence Typing 
CA-MRSA community-acquired methicillin-resistant Staphylococcus aureus 
CC clonal complex 
CFU colony forming units 
CLED cystine lactose electrolyte-deficient agar 
CLSI Clinical and Laboratory Standards Institute (formerly NCCLS) 
CoNS coagulase negative Staphylococcus
CSF cerebrospinal fluid 
EARSS European Antibiotic Resistance Surveillance System 
fem factors essential for methicillin resistance 
FiRe Finnish Study Group for Antimicrobial Resistance  
HA-MRSA hospital-acquired MRSA 
HCW health-care ward 
HD hospital district 
KTL National Public Health Institute (Kansanterveyslaitos) 
kDa kilodalton 
LTF long-term facility 
Mbp mega-base-pare 
MDR multi-drug-resistant 
mecA gene coding for penicillin-binding protein 2a (PBP2a) 
MIC minimum inhibitory concentration 
MH Müller-Hinton agar 
MRSA methicillin-resistant Staphylococcus aureus 
GlcNAc  N-acetylglucosamine 
MurNAc N-acetylmuramic acid 
NaCl sodium chloride 
NCCLS National Committee for Clinical Laboratory Standards 
NH nursing home 
NIDR National Infectious Disease Register 
NMDR non-multi-drug-resistant 
NNIS National Nosocomial Infection Surveillance System (USA) 
NRL National Reference Laboratory 
nuc nuclease 
MLST multilocus sequence typing 
MSA mannitol salt agar 
ORSAB Oxacillin Resistance Screening Agar Base 
PBP penicillin-binding protein 
PCR polymerase chain reaction 
PFGE pulsed-field gel electrophoresis 
PVL Panton-Valentine leukocidin 
RFLP restriction fragment length polymorphism 
sar staphylococcal accessory gene regulator 
SBA sheep blood agar 
SCCmec staphylococcal cassette chromosome mec 
SRE right extremity regions 
4ST sequence type 
TSST-1 toxic shock syndrome toxin-1 
VISA vancomycin intermediate-resistant Staphylococcus aureus
VRSA vancomycin-resistant Staphylococcus aureus
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61. INTRODUCTION 
Methicillin-resistant Staphylococcus aureus (MRSA) has become one of the most commonly 
identified antibiotic-resistant pathogens in many parts of the world, including Europe, the Americas, 
North Africa, the Middle East, and East Asia. In recent decades, MRSA rates have been increasing 
worldwide, including in the Nordic countries and the Netherlands, where MRSA rates have been 
low and stable for many years (Fridkin et al., 2002; Tiemersma et al., 2004; Turnidge and Bell, 
2000). Evidence suggests that MRSA infections of nosocomial origin increase morbidity, mortality, 
and costs (Cosgrove et al., 2005; Cosgrove et al., 2003; Engemann et al., 2003), and may cause 
patient suffering and harm both psychologically and financially (Tarzi et al., 2001).  
Infections caused by MRSA can also be acquired outside health care settings, and specifically in the 
community. Community-acquired (CA) MRSA has most often been reported in persons or groups 
with a high intensity of physical contact, which may aid transmission (CDC, 2003a; CDC, 2003b; 
Groom et al., 2001; Zinderman et al., 2004). When hospital-acquired (HA) MRSA strains are 
known to spread to the community, community-based strains may also migrate into health care 
settings, thus creating a two-way flow of MRSA (de Trindade et al., 2005; Kilic et al., 2006; 
Seybold et al., 2006). Some researchers have suggested that long-term facilities (LTF) such as 
nursing homes (NH) may be reservoirs of MRSA and, therefore, be responsible for the introduction 
of this organism into the health care setting (Bradley, 1999). Controlling infection in NHs is 
challenging because residents should be able to live as normal a life as possible. 
Active surveillance cultures for patients at high risk for MRSA colonization or infection, together 
with contact precautions, are essential to decrease the incidence of nosocomial MRSA infections 
(Muto et al., 2003). Clinical microbiology laboratories play a pivotal role in the diagnosis and 
antibiotic susceptibility testing of MRSA. Low-level oxacillin resistance among MRSA is a 
particular diagnostics problem, and in practice this problem becomes even more important when S. 
aureus strains are resistant only to oxacillin (Fang and Hedin, 2003; Merlino et al., 2002b; Safdar et 
al., 2003). False negative results may lead to treatment failure and the spread of MRSA due to 
miscalculation of infection control practices. On the other hand, MRSA strains susceptible to very 
few antibiotics exist. Vancomycin, a glycopeptide antibiotic, is the treatment of choice for serious 
MRSA infections, especially those with multi-drug-resistant strains. In 1996, however, the first 
clinical vancomycin intermediate-resistant S. aureus (VISA) was documented (Hiramatsu et al., 
1997), and VISA strains have subsequently been isolated around the world, although they have 
remained rare (Walsh and Howe, 2002). In addition, three S. aureus strains with full resistance to 
vancomycin (VRSA) have been reported thus far (CDC, 2002a; CDC, 2002b; CDC, 2004; Chang et 
al., 2003; Tenover et al., 2004).  
A functional, active surveillance system is needed for monitoring the constantly changing 
epidemiology of MRSA (Coia et al., 2006; Gould, 2005). Outbreak investigation and consecutive 
control measures have been proven to be cost-effective, at least in situations with a low-prevalence 
of MRSA (Björholt and Haglind, 2004; Vriens et al., 2002). The ability to discriminate accurately 
between MRSA isolates is crucial in investigating their spread on a local level, and pulsed-field gel 
electrophoresis (PFGE) has been lauded as the gold standard for that purpose (Tenover et al., 1994). 
When looking at the global epidemiology of MRSA (Robinson and Enright, 2003), multi-locus 
sequence typing (MLST) and the mobile genetic element, staphylococcal cassette chromosome mec
(SCCmec) -typing (Enright et al., 2000; Ito et al., 2004; Oliveira and de Lencastre, 2002) are more 
useful.  
7Because continuously increasing numbers of MRSA cases were reported to the National Infectious 
Disease Register (NIDR) at the National Public Health Institute (KTL), and an equal number of 
MRSA isolates were sent to the National Reference Laboratory (NRL) for further confirmation and 
typing, the reasons behind the changing epidemiology of MRSA were investigated. The data 
obtained from the NIDR and NRL from 1997 to 2004 was analyzed, the studies of S. aureus/MRSA 
colonization and prevalence in nursing homes using molecular typing techniques were performed 
and the screening methods were assessed, and the phenotypic and genotypic methods of detecting 
MRSA were evaluated, in an attempt to bring appropriate information to clinical microbiology 
laboratories. 
82. REVIEW OF THE LITERATURE 
2.1 Staphylococcus aureus
2.1.1 Structure, virulence factors, and pathogenesis 
Staphylococcus aureus is a facultative aerobic gram-positive coccus living alongside humans and 
animals as an opportunistic pathogen. S. aureus consists of cytosol, a single cytoplasmic membrane, 
and the surrounding cell wall. The cell wall of S. aureus is mainly peptidoglycan, composed of 
repeating disaccharide N-acetylglucosamine-N-acetylmuramic acid (GlcNAc-MurNAc) units with 
attached teichoic acids (Navarre and Schneewind, 1999). Glycan chains are crosslinked by 
tetrapeptides consisting of L-alanine, D-glutamate, L-lycine, and L-alanine to pentaglycine 
interbridge, linked to wall peptide. The main function of peptidoglycan is to provide a rigid 
envelope for the cell contest. Peptidoglycan also has endotoxic properties, and has been reported to 
cause organ dysfunctions in experimental animals (Holtfreter and Broker, 2005). There are 
numerous other bacterial components and secreted products, such as virulence factors, that affect 
the pathogenesis of S. aureus. Teichoic acids, another cell wall component, have been found not 
only to establish nasal colonization (Aly and Levit, 1987; Weidenmaier et al., 2004), but also to 
contribute together with peptidoglycan to the severity of staphylococcal sepsis (De Kimpe et al., 
1995). The cell wall assembly is catalysed by high molecular weight bifunctional enzymes, 
penicillin-binding proteins (PBP). Four native forms of PBPs (1-4) promote the polymerization of 
glycan from its disaccharide precursor, and from the transpeptidation of wall peptides (Navarre and 
Schneewind, 1999). Most S. aureus strains produce a slimy, extracellular capsular polysaccharide. 
A total of eight capsular serotypes have been described, and serotypes 5 and 8 account for 
approximately 25% and 50%, respectively, of isolates found in humans (O'Riordan and Lee, 2004).  
The adherence of S. aureus to host tissue is an important step in pathogenesis as well as in 
colonization. Surface proteins such as protein A, clumping factors, fibronectin-binding proteins, and 
collagen-binding proteins can adhere to extracellular matrix components of the host (Foster and 
Hook, 1998). The main function of protein A, however, is to bind the IgG Fc-domaine. Almost all 
strains produce and secrete enzymes and exotoxins including hemolysins (alpha, beta, gamma, and 
delta), proteases, lipases, nucleases, hyalonuridase, and collagenase (Dinges et al., 2000). Some 
toxins, such as toxic shock syndrome toxins (TSST-1) or enterotoxins (SEA, SEB, SECn, SED, 
SEE, SEG, SHE, and SEI) produced by some strains, are sufficient to cause specific diseases, 
whereas no single virulence factor has been shown to cause an inflammatory process. For example, 
to cause systemic diseases such as bacteremia, S. aureus must produce components capable of 
attaching to cells or tissues, factors that decrease phagocytosis in order to escape the host immune 
system, and to modify proteases, exotoxins, and enzymes, causing tissue damage, and thus, 
allowing the dissemination of S. aureus. Some strains also produce exfoliative toxins (ETA and 
ETB), and leukocidins such as Panton-Valentine leukocidin (PVL). PVL genes encode a 
bicomponent leukotoxin, which comprises pore-forming staphylococcal toxins together with alpha- 
and gamma-haemolysins (Prevost et al., 2001). To date, 11 leukotoxin proteins have been 
identified: six of class S proteins (LukSPV, LukE, LukM, HlgA, HlgC, and LukSI) and five of class 
F proteins (LukFPV, LukD, LukF’PV, HlgB, and LukFI) (Prevost et al., 2001). These proteins may 
be required to break the tissue down into nutrient components for bacterial growth. The primary 
function of these toxins may still be to inhibit the host immune response, although they also have 
potent effects on cells. Injecting PVL into the skin of rabbits has been reported to cause dermal 
necrosis (Ward and Turner, 1980), suggesting that it may cause severe skin infections in humans. 
9Studies have reported an association between PVL containing MRSA strains and virulent 
necrotizing pneumonia (Gillet et al., 2002). 
2.1.2 Genome 
The genome of S. aureus consists of a single circular chromosome (2.7-2.9 Mbp) containing about 
2600 genes. Whole genome sequences have been reported for nine S. aureus isolates: COL, NCTC 
8325, N325, Mu50, MW2, MRSA252, MSSA476, RF122, and USA300-FPR3757 
(http://cmr.tigr.org/tigr-scripts/CMR/shared/Genomes.cgi/, http://www.genome.ou.edu/staph.html/,  
http://www.sanger.ac.uk/Projects/S_aureus/). Phylogenetic studies have indicated that more than 
half of the predicted proteins encoded by the S. aureus genome are similar to those of Bacillus 
subtilis and Bacillus halodurans (Kuroda et al., 2001). These typically include proteins encoded by 
house-keeping genes essential for absorbing nutrients from the environment, metabolic intermediate 
synthesis, and reproduction. Eight genomic islands conferring pathogenity or antibiotic resistance 
have been found on the S. aureus chromosome (Ito et al., 2003). There is also an assortment of 
extrachromosomal accessory genetic elements: conjugative and nonconjugative plasmids, mobile 
elements, prophages and other variable elements. 
2.1.3 Carriage 
Humans are a natural reservoir of S. aureus and the primary ecological niches of S. aureus are the 
anterior nares, although other body sites such as the throat, perineum, groin, and skin may also be 
colonized with S. aureus. S. aureus nasal carriage has been identified as a major risk factor in the 
development of infections not only in the hospital setting (Corbella et al., 1997; Kluytmans et al., 
1995; von Eiff et al., 2001), but in the community as well (Wertheim et al., 2005). Many underlying 
diseases or conditions such as insulin-dependent diabetes mellitus, continuous ambulatory 
peritoneal dialysis (CAPD), intravenous drug abuse, human immunodeficiency virus (HIV) 
infection or AIDS, and S. aureus skin infections and other skin diseases have been associated with a 
higher S. aureus nasal carriage and subsequent infection rate (Berman et al., 1987; Luzar et al., 
1990; Nguyen et al., 1999; Williams et al., 1998). According to cross-sectional studies, a mean 
carriage rate of 37% was found when investigating the prevalence and incidence of S. aureus nasal 
carriage (Kluytmans et al., 1997). However, the range has been reported to be large: 9-100%. The 
reason for such a high range of carriage rates may be due to differences in the quality of sampling 
and in the laboratory techniques used to culture specimens. The S. aureus nasal carriage rate may 
also have changed over the years; previous studies have reported higher rates than those published 
recently (Kluytmans et al., 1997; Wertheim et al., 2005).  
Nasal carriage patterns differ between healthy persons, and persistent carriage has been reported in 
10-35% of individuals, 20-75% carry S aureus intermittently, and 5-50% never carry S. aureus 
(Kluytmans et al., 1997). The non-carrier state may be attributable to bacterial interference with 
each other: when the ecological niche is already occupied by other bacteria such as coagulase-
negative staphylococci (CoNS) or Corynebacterium species, S. aureus does not seem to replace the 
resident bacterial population (Hu et al., 1995). Persistent carriage is more common in young 
children than in adults, and the carriage pattern has been reported to change in many persons 
between age 10-20 (Armstrong-Esther, 1976). In addition, a persistent carriage rate is higher in 
males than in females, and depends on hormonal status (Eriksen et al., 1995; Winkler et al., 1990). 
Significantly higher numbers of S. aureus bacteria have been reported in the nostrils of persistent 
carriers than in those of intermittent carriers, which results in an increased risk of S. aureus
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infections; elderly healthy persistent carriers had higher amounts of S. aureus bacteria than did 
young carriers (Nouwen et al., 2004). Based on molecular studies, the exchange rate of S. aureus
strains has been reported to be significantly higher in intermittent carriers than in persistent carriers 
(van Belkum et al., 1997; VandenBergh et al., 1999). No common genetic or phenotypic 
characteristics segregating persistent from intermittent colonizing strains have been found thus far, 
although much research has focused on specific staphylococcal factors and interactions with host 
components (Biesbrock et al., 1991; Patti et al., 1994; Sanford et al., 1989; van Belkum et al., 
1997).  
Cespedes and colleagues have developed a mathematical model for investigating the frequency of 
the simultaneous nasal carriage of multiple strains of S. aureus (Cespedes et al., 2005). According 
to that study, 6.6% of S. aureus-colonized individuals carry more than one strain. The presence of 
more than one strain of S. aureus at the same time increases the potential for the horizontal transfer 
of genes, including virulence determinants or antimicrobial-resistance genes. This may be a 
problem when a single antibiotic-susceptible isolate, rather than another, more resistant strain from 
patients infected with S. aureus is only detected. The treatment may therefore be unsuitable.  
2.1.4 S. aureus infections 
S. aureus is one of the most important bacteria that cause disease in humans. It is the most common 
cause of skin and soft tissue infections such as abscesses, carbuncles, folliculitis, furuncles, 
impetigo, bullous impetigo, and cellulitis. Most skin infections resolve without treatment within a 
few weeks, although some infections require incision and drainage or antibiotics to cure the 
infection. Skin infections left untreated can, however, develop into more serious infections such as 
bloodstream infection and septic shock (Lina et al., 1999; Lindenmayer et al., 1998). Other life-
threatening infections caused by S. aureus include endocarditis, pneumonia, scalded skin syndrome, 
or bone and joint infections. Serious infections typically require hospitalization and treatment with 
intravenous antibiotics. S. aureus was the most frequently isolated pathogen from skin and soft 
tissue infections in the USA, Canada, Latin America, Western Pacific and Europe, and was the most 
commonly found pathogen causing bloodstream infection and pneumonia in almost all geographic 
areas (Diekema et al., 2001). In Finland, S. aureus has been reported to cause 700-900 septic 
infections annually (Lyytikäinen et al., 2002), and to be the second most common pathogen causing 
hospital-acquired infections in general (Lyytikäinen, 2005). In addition, the annual incidence of 
bloodstream infections caused by S. aureus has risen from 11 per 100,000 population in 1995 to 17 
in 2001, and the increase was most distinct in patients over 74 years of age (Lyytikäinen et al., 
2005). Catheter-related infections and postoperative wound infections are also commonly 
associated with S. aureus. In fact, intravascular catheter-related infections are the primary cause of 
nosocomial bacteremia (Eggimann and Pittet, 2002). Toxic shock syndrome (TSS) and food 
poisoning are toxin-mediated diseases caused by TSST-1 and enterotoxin-producing strains of S. 
aureus, respectively. TSS is an acute, multisystem disease with symptoms such as high fever, 
hypotension, desquamation of the skin, and dysfunction of multiple organ systems (Dinges et al., 
2000). Although TSS is most commonly believed to be related to tampon use, toxin-producing S. 
aureus strains have also been isolated from children with major systemic non-invasive illness 
(Dinges et al., 2000). S.  aureus can grow in a variety of foods because it withstands a wide range of 
temperatures, pH conditions, and sodium chloride (NaCl) concentrations (Le Loir et al., 2003).The 
symptoms of food poisoning caused by S. aureus include abdominal cramps, nausea, and vomiting, 
sometimes followed by diarrhea. The onset of symptoms is rapid (from 30 min to 8 h) and the 
symptoms will usually pass spontaneously after 24 h.  
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2.2 Methicillin-resistant S. aureus
2.2.1 Methicillin resistance 
Methicillin resistance in staphylococci is due primarily to the acquisition of a mobile staphylococcal 
chromosomal cassette which carries the mecA-gene, known as SCCmec (Katayama et al., 2000). 
This mecA-gene encodes an altered PBP, PBP2a (or PBP2’), that is 78 kDa in size (Hartman and 
Tomasz, 1984). Methicillin, like all beta-lactam antibiotics, mimics the structure of D-alanine-D-
alanyl, which is the target of a transpeptidation reaction catalyzed by PBPs (Navarre and 
Schneewind, 1999). The affinity of beta-lactams towards PBP2a is much lower than towards native 
PBP2, thus allowing continuous cell wall assembly (Reynolds and Brown, 1985).  
To date, researchers have identified five types of SCCmec elements (Figure 1) and several variants 
(Boyle-Vavra et al., 2005; Ito et al., 2001; Ito et al., 2004; Ma et al., 2002; Oliveira and de 
Lencastre, 2002; Oliveira et al., 2001; Shore et al., 2005). Each SCCmec type integrates at the same 
site (attBscc) located near the S. aureus origin of replication in the orfX gene of unknown function 
(Ito et al., 1999). For movement, SCCmec carries three specific genes, designated cassette 
chromosome recombinases A, B, and C2 (ccrA, ccrB, and ccrC), which encode recombinases of the 
invertase/resolvase family (Boyle-Vavra et al., 2005; Ito et al., 1999; Ito et al., 2004). In addition to 
the mecA gene, the class A mec gene complex contains two intact genes; mecI encodes a 
transcription repressor protein, and mecR1, a signal-transduction protein (Hiramatsu et al., 2001). 
Class B mec complex contains mecA, but mecI and part of the mecR1 are deleted, and a truncated 
copy of an insertion sequence, IS1272, is integrated into this deletion. Class C2 mec comprises of a 
copy of insertion sequence IS431, mecA, a truncated copy of mecR1, and another copy of IS431
(SCCmec V) (Ito et al., 2004) or of truncated transposase in IS431 (SCCmec VT) (Boyle-Vavra et 
al., 2005).  
Type I SCCmec carries class B mec and type 1 ccr; type II SCCmec possesses class A mec and type 
2 ccr; type III SCCmec has class A mec and type 3 ccr; type IV contains class B mec and type 2 ccr; 
and type V comprises class C mec and type 5 ccr. The mecA gene is the only resistance gene 
involved in types I, IV, and V SCCmec elements. SCCmec types II, III, and IIIA, on the contrary, 
carry phage Tn554, which encodes for resistance to macrolides, lincosamines and streptogramins. 
In addition, both SCCmec IA and II carry phages pUB110, which encodes for resistance to 
tobramycin, and pG01, which encodes resistance to gentamycin and trimetoprim. SCCmec III 
carries pT181 encoding resistance for tetracycline (Deresinski, 2005; Hiramatsu et al., 2001). In 
general, SCCmec types I, II and III are considered mainly as hospital-acquired (HA), and SCCmec
types IV and V as community-acquired (CA). 
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Figure 1. SCCmec types I-V according to published strain types. Type I, strain NCTC10442 (Ito, 2004); type II strain 
N315 (Ito, 1999); type III strain 85/2082 (Ito, 2001); type IV, strain 8/6-3P (Ma, 2002); type V, strain WIS (Ito, 2004). 
The mec gene complex appears in red, the ccr gene complex in green, insertion sequences (IS431 or IS1272) in orange, 
elements encoding resistance to antimicrobials other than betalactams (Tn554, ΨTn554, pUB110, and pT181) in 
yellow, the orfX gene of unknown function in blue, and other elements (genes) in white or in grey. 
Various SCCmec types are widely distributed among staphylococcal species other than S. aureus. 
Several findings support the understanding that the intra- and interspecies transfer of genetic 
information may occur through a mobile SSC element. First, the origin of SCCmec is unknown, but 
a close homologue of the S. aureus mecA gene has been identified in S. sciuri, of both animal and 
human origin (Couto et al., 1996; Couto et al., 2000). Second, since the IS1272 element seems to be 
intact and exists in multiple copies in the genome of S. haemolyticus, IS1272 usually contains 
deletions in S. aureus and in Staphylococcus epidermidis. Thus, some researchers have suggested 
that S. haemolyticus acquired IS1272 before S. aureus and Staphylococcus epidermidis did (Archer 
et al., 1996; Kobayashi et al., 1999). Third, one recent study has reported an MRSA in-vivo
formation by the horizontal transfer of mecA during antibiotic treatment between Staphylococcus 
epidermidis and S. aureus (Wielders et al., 2001). Fourth, an SCC without the mecA gene complex 
has been identified in S. aureus strain, which carries a cap operon instead of an antibiotic resistance 
gene (Luong et al., 2002). Finally, clinically significant Staphylococcus epidermidis isolates were 
reported to harbour SCCmec type IV, which was identical in size and 98% homologous to DNA 
sequences for S. aureus (Wisplinghoff et al., 2003).  
Many clinical MRSA isolates express resistance to methicillin heterogeneously. This means that the 
majority of cells are susceptible to low concentrations of methicillin, and only a minority of cells 
can grow at high concentrations. In addition to mecA, other resistance mechanisms are also needed 
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for the expression of methicillin resistance in S. aureus. Factors essential to methicillin resistance 
(fem) or auxillary (aux) factors involved in peptidoglycan synthesis include normal chromosomal 
genes of S. aureus, of which defective mutants inhibit precursor formation. In addition, ilm and 
global regulators agr and sar genes may influence methicillin resistance (Berger-Bachi, 1994; 
Chambers, 1997). Deletions and mutations in mecI or mutations in the promoter region of mecA
may result in heterogeneous resistance (Kobayashi et al., 1998; Shukla et al., 2004; Suzuki et al., 
1993). In addition, partial deletion of the regulatory genes and absence of beta-lactamase regulatory 
genes (blaI and blaR1) result in the constitutive production of PBP2a (Hackbarth and Chambers, 
1993). The production of PBP2a, however, is strongly repressed in MRSA strains containing fully 
functional and intact mec regulatory genes. Those isolates, although possessing mecA, seem to be 
susceptible by conventional testing. Confusion sometimes arises in the terminology of 
heterogeneous resistance and borderline resistance. Borderline resistance in S. aureus isolates is due 
to either penicillinase hyper-production (termed BORSA) or to modifications of the PBPs 
(sometimes termed MODSA). Borderline-resistant S. aureus strains never carry mecA gene, and are 
therefore not MRSA. 
2.2.2 Public health importance 
Methicillin was first introduced in 1959 to treat infections caused by penicillin-resistant S. aureus. 
In 1961, reports emerged from the UK of S. aureus isolates resistant to that new antibiotic (Jevons, 
1961). Soon MRSA strains were found in other European countries, and later in Japan, Australia 
and the USA. Currently, MRSA is the most commonly identified antibiotic-resistant pathogen in 
US hospitals (Diekema et al., 2004a; NNIS, 2004), and its proportion in intensive care units has 
increased from 35.9% in 1992 to 64.4% in 2003 (Klevens et al., 2006). In Europe, the proportion of 
invasive isolates resistant to oxacillin, another anti-staphylococcal penicillin which later became a 
substitute for methicillin, varies from <1% to >50% (EARSS, 2006). In the UK, for example, the 
proportion of invasive MRSA isolates has increased from 2% in 1990 to a peak of 43% in 2002, 
with a slight decline thereafter (Johnson et al., 2005), whereas in the Nordic countries and the 
Netherlands, the proportion remains less than 5% (EARSS, 2006). Reports indicate that mortality 
due to MRSA infections increased in England and Wales during the period 1993-2005 (Crowcroft 
and Catchpole, 2002; NationalStatistics, 2007). A meta-analysis study estimated the death rate for 
patients with MRSA bacteremia to be approximately twice higher than the death rate due to the 
bacteremia caused by methicillin-sensitive S. aureus (MSSA) (Cosgrove et al., 2003), although no 
greater intrinsic virulence of MRSA has been detected (Hershow et al., 1992). In addition, MRSA 
infections are responsible for lengthier periods of hospitalization and increased costs (Cosgrove et 
al., 2005). Reports attribute extra costs to extra days spent in hospital, antimicrobials for treating the 
infection, and laboratory diagnostics (Björholt and Haglind, 2004; Muto et al., 2003). 
In general, countries with stringent control measures tend to report low MRSA incidence rates 
(Salmenlinna et al., 2000; Verhoef et al., 1999). The ‘search and destroy’ policy applied in the 
Nordic countries and the Netherlands requires that all patients at risk for MRSA carriage be isolated 
and screened before admission to hospital (EARSS, 2006). To recognize outbreaks, to reduce 
infection rates and thereby morbidity, to improve care, and to reduce costs in health care settings 
requires a functional surveillance system (Roy and Perl, 1997). Systematic data collection from 
participating instances in the surveillance system, epidemiological and microbial data analysis, and 
information feedback on the instances providing the data are the key steps of an effective 
surveillance system. The precise definitions and methods used, however, depend on the surveillance 
demanded. Surveillance can be performed at the local, national or international level, and may be 
restricted to certain units or other restricted areas. For example, National Nosocomial Infection 
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Systems (NNIS) collects and analyses data from intensive care units, high-risk nurseries, and 
surgical patients in US hospitals (NNIS, 2004). In addition, the international antimicrobial 
surveillance system European Antibiotic Resistance Surveillance System (EARSS) performs 
continuous surveillance of the seven most important bacterial pathogens that cause invasive 
infections and monitors variations in antimicrobial resistance over time and place 
(www.earss.rivm.nl). Moreover, The SENTRY Antimicrobial Surveillance Program collects 
antimicrobial resistance data on bacteria responsible for bloodstream infections, skin and soft-tissue 
infections, and pneumonia (Diekema et al., 2000; Diekema et al., 2001; Pfaller et al., 1998; Pfaller 
et al., 1999). 
Besides being a significant problem in hospitals, MRSA can cause infections in the community. 
Such novel MRSA strains were observed for the first time in 1993 among Indigenous Australian 
patients who had had no previous contact with health care systems (Udo et al., 1993). In 1999, four 
pediatric deaths resulting from CA-MRSA infections were reported, thus generating greatly 
increased interest in this organism among health care providers (CDC, 1999). Recently, increasing 
numbers of MRSA infections from persons unassociated with health care facilities have been 
reported worldwide (Aires de Sousa et al., 2005; Borer et al., 2002; Bratu et al., 2005; Carleton et 
al., 2004; Harbarth et al., 2005; Hsu et al., 2006; Ma et al., 2005; Mishaan et al., 2005; Mulvey et 
al., 2005; O'Brien et al., 2004; Salmenlinna et al., 2002; Söderquist et al., 2006; Takizawa et al., 
2005; Urth et al., 2005). Outbreaks of CA-MRSA infections, especially skin and soft-tissue 
infections, have been described among members living in closed communities or having had direct 
skin-to-skin contact, as with competing athletes, prison inmates, military recruits, and children in 
child care centers (CDC, 2003a; CDC, 2003b; Lindenmayer et al., 1998; Shahin et al., 1999; 
Zinderman et al., 2004).  
The SCCmec types IV and V typical of CA-MRSA are quite small and can easily be packed and 
transferred horizontally to other staphylococcal strains. The proportional increase of MRSA strains 
susceptible to a wide variety of antimicrobials, which are probable CA-MRSA isolates, suggests 
that the epidemiology of MRSA is changing. One study suggested that CA-MRSA strains may be 
better able to adhere to epithelial cells than are HA-acquired MRSA strains (Adhikari et al., 2002). 
Reports of the CA-MRSA strains’ higher tolerance for salt than that of nosocomial strains suggest 
that it may improve its ability to survive as skin flora (Adhikari et al., 2002). The ability of CA-
MRSA strains to colonize hosts in the community and to cause infections is mediated by several 
virulence factors. Analysis of the genome of one CA-MRSA strain, MW2, demonstrates 19 unique 
genes encoding virulence factors not found on other S. aureus genomes sequenced thus far (Baba et 
al., 2002). The most well-known CA-MRSA virulence factor is PVL, which is a potent necrotizing 
toxin. Furunculosis is the most frequently reported presentation of CA-MRSA infection, and most 
of the CA-MRSA strains that cause epidemic furunculosis carry PVL genes (Lina et al., 1999; 
Zetola et al., 2005). The definitions of CA-MRSA used in the literature have varied over the years 
(Salgado et al., 2003; Zetola et al., 2005). Epidemiologically, all MRSA infections acquired outside 
of the health care setting or acquired within 48-72 h after hospitalization are by definition 
community-acquired. This may, however, overestimate the problem of CA-MRSA if data from 
previous health care contacts are unavailable (Salgado et al., 2003). The presence of SCCmec types 
IV or V, and/or the expression of lukS-PV and lukF-PV genes that encode for PVL, along with 
epidemiological data is also used in defining of CA-MRSA (Coombs et al., 2004; Diep et al., 2004; 
Liassine et al., 2004; Vandenesch et al., 2003). Although many strains found in the community 
harbor these markers, the transmission of “CA-MRSA” strains between health care settings and the 
community may occur (de Trindade et al., 2005; Kilic et al., 2006; Seybold et al., 2006). 
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2.3 MRSA in long-term facilities  
S. aureus infection is a serious problem among the elderly in acute care. Complications and death 
from the most severe staphylococcal infections such as endocarditis, pneumonia, meningitis, and 
septic arthritis are common among persons over the age of 65 (Espersen et al., 1991; Jensen et al., 
1993; McGuire and Kauffman, 1985; Terpenning et al., 1987; Terpenning et al., 1988). With the 
increasing number of elderly people whose care has been moved outside of acute care, S. aureus
and especially MRSA infections have become a major issue in LTF. 
2.3.1 Epidemiology 
Colonization with S. aureus occurs predominantly in the nostrils, skin, rectum, and perineum 
(Bradley, 1999). MRSA colonization rates in LTF vary, but the highest colonization rates have been 
obtained from samples taken from the nostrils and wounds. Previous studies from the USA, the UK, 
Australia, and Japan have reported the prevalence of MRSA among residents to vary from 8% to 
53% (Bradley, 1997), whereas recently published, mainly European studies have reported a 
prevalence of 0.7% to 10.1% (Cretnik et al., 2005; de Neeling, 2003; Hoefnagels-Schuermans et al., 
2002; Mendelson et al., 2003; O'Sullivan and Keane, 2000b; von Baum et al., 2002). Differences in 
colonization rates may depend on a variety of factors such as the prevalence of MRSA in 
transferring from one health care institution to another, the presence of an outbreak of MRSA 
infections, the type and severity of the residents’ underlying condition, and the infection control 
practices at the LTF (Bradley, 1999). In a nursing home (NH) where MRSA was endemic and 
multiple sites of residents were cultured monthly, 65% of patients never acquired MRSA, 25% were 
colonized with MRSA before admission to the nursing home, and 10% acquired MRSA during their 
nursing home stay (Bradley et al., 1991). Longitudinal studies indicate that, once colonized among 
NH residents, colonization seems to be persistent (Bradley et al., 1991; Mulhausen et al., 1996). In 
endemic settings, residents have been reported to be colonized with many different MRSA strains 
(Bradley et al., 1991; Drinka et al., 2005; Muder et al., 1991) in contrast to epidemic situations 
where one or two strains circulate. MRSA colonization is probably common in LTF because, along 
with the potential for acquisition in the NH itself, residents already colonized from other facilities
continue to be admitted, MRSA carriage persists, and the length of stays are long.  
2.3.2 Risk factors 
Not all residents in NHs appear to be at the same risk for colonization by MRSA. Several studies 
have identified current antibiotic therapy, male gender, the presence of invasive devices, the 
presence of pressure sores or wounds, the presence of catheters, hospital admission, and prior 
MRSA colonization as risk factors (Hsu, 1991; Mendelson et al., 2003; Niclaes et al., 1999; 
O'Sullivan and Keane, 2000a; von Baum et al., 2002; Vovko et al., 2005). Persons colonized with S. 
aureus or MRSA are generally at increased risk of becoming infected. In such cases, the infection is 
typically caused by the colonizing strain. Rates of MRSA infections, however, do not seem to 
approach those of asymptomatic MRSA colonization (Bradley, 1997; Bradley, 1999; Bradley et al., 
1991; Muder et al., 1991). More than half of these infections involve skin and soft tissue or urinary 
track infections, and hospital care is required primarily for the administration of intravenous 
antimicrobials. Although MRSA infection rates are low in NHs, studies show that residents 
colonized with MRSA have a four- to six-fold higher risk of developing an MRSA infection than do 
noncolonized residents (Muder et al., 1991; Mulhausen et al., 1996). 
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2.3.3 Management 
Interest in the epidemiology of infection and its control in LTFs and NHs has grown in recent 
decades as increasing numbers of elderly people are treated in acute and high-risk units, and then 
transferred to LTFs. In addition to hospital-acquired MRSA, LTFs with endemic MRSA may 
represent a reservoir of MRSA, and therefore create a two-way flow of MRSA between hospitals 
and LTFs. To prevent the transmission of MRSA between patient and health care staff, appropriate 
infection control practises must exist (Bradley, 1999). Lack of resources may be one of the major 
limitations in infection control practices; a full-time infection control practitioner with formal 
training and optimal patient-to-nurse ratios are only seldom available. Thus, infection control 
procedures must be sufficiently simple for health care technicians and other non-medically educated 
personnel to follow. In general, functional control precautions of acute care may be adapted to LTF 
(MRSA-asiantuntijatyöryhmä, 2004; Muto et al., 2003). There are, however, some special 
challenges with regard to controlling MRSA (or other infectious agents) because they deal with a 
setting considered to be the resident’s own home. Residents should be able to live their normal lives 
regardless of MRSA colonization, but at the same time transmission of MRSA to other residents 
must be prevented. The most important activity is to prevent an epidemic of MRSA in LTF 
beforehand (MRSA-asiantuntijatyöryhmä, 2004). In an epidemic situation, MRSA-infected or -
colonized residents should be isolated in private rooms or cohorted. Cohorting several MRSA-
positive residents into the same room is an effective means of preventing the spread of MRSA 
during an outbreak of infection (Murray-Leisure et al., 1990), but its routine use limits the daily 
activities of residents. Intensified hand hygiene is very important in an epidemic situation. Since 
MRSA most commonly spreads to patients by direct contact through the contaminated hands of the 
nursing staff, routine practice should include cleaning hands with an antiseptic-containing solution 
before and after all patient contact (Bradley, 1999; Muto et al., 2003). In addition, changing gloves 
between residents and wearing gowns is necessary when there exists a risk of contact with blood or 
body fluids. The successful eradication of MRSA colonization with oral or topical (mupirocin) 
antibiotics has also been reported (Kotilainen et al., 2001), although efforts to control MRSA in a 
LTF setting have generally been incompletely effective (Cederna et al., 1990) or even unsuccessful 
due to a significant increase in the number of high-level mupirocin-resistant MRSA isolates 
(Vasquez et al., 2000). Active surveillance cultures of the residents should be done in an epidemic 
situation at a frequency based on the prevalence of MRSA and on risk factors for colonization 
(Muto et al., 2003). Surveillance cultures for MRSA should always include samples from the 
nostrils and, if present, from skin defects. Throat and perirectal-perineal cultures have been shown 
to detect S. aureus and MRSA with a high degree of sensitivity, but should not be selected as the 
only sites for a culture (Muto et al., 2003). The screening of the nostrils, the throat, and the 
perineum together have been reported to detect 98% of all carriers studied (Coello et al., 1994). 
Effectively tracking an MRSA outbreak entails keeping records of the date on which the MRSA-
positive culture was performed, the site or type of infection, the contacts, the location in the facility, 
and antibiotic resistance patterns (Bradley, 1999; Mulligan et al., 1993). Molecular typing 
differentiates epidemic from nonepidemic strains, although these results may not be readily 
available to most nursing homes. 
2.4 Laboratory diagnostics of MRSA 
Reliable microbiological diagnostics of MRSA are essential for treatment, surveillance and control. 
Clinical microbiology laboratories play a central role in the detection, identification, antibiotic 
susceptibility testing, and confirmation of MRSA. Conventional laboratory detection of MRSA 
includes culturing the specimen with or without enrichment broth, confirmation of S. aureus with 
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identification tests, antimicrobial susceptibility testing, and finally, verification of MRSA, usually 
with molecular methods. This may take several days, however, and may therefore prolong 
unnecessary contact precautions and isolation measures in health care facilities. Rapid diagnostic 
testing for MRSA directly from specimens allows the infected patient to obtain a more rapid 
verification of antimicrobial therapy, leading to a decrease in mortality, a reduction in vancomycin 
usage, shorter stays in hospital, and lower hospital costs (Bootsma et al., 2006; Diekema et al., 
2004b). Rapid tests are still more expensive than conventional ones, and not all laboratories are able 
to use them for financial reasons. In Finland, however, only a little experience with these tests 
currently exists. Regardless of the diagnostics methods used, concomitant cultures are necessary to 
recover the organism for further antimicrobial susceptibility testing and for epidemiological typing. 
2.4.1 Culturing of MRSA 
MRSA may be found in a culture on sheep blood agar (SBA) or other non-selective media in 
normal routine laboratory diagnostics. Resistance of S. aureus to oxacillin or cefoxitin or both in 
antimicrobial susceptibility testing usually leads to a suspicion of MRSA. This usually takes two to 
three days, and the isolate subsequently remains to be confirmed (discussed below). To achieve 
greater rapidity and sensitivity, screening specimens for MRSA detection are frequently cultivated 
onto selective media. These media contain an indicator to distinguish S. aureus, inhibitory agents to 
suppress non-staphylococcal growth, and antibiotics, usually oxacillin or cefoxitin, to select for 
MRSA isolates. Mannitol salt agar (MSA) or variations of this medium have been widely used as a 
primary isolation medium for MRSA. Its reported sensitivity and specificity have varied widely 
(Apfalter et al., 2002; Diederen et al., 2006; Kampf et al., 1998; Louie et al., 2006; Merlino et al., 
2002a; Safdar et al., 2003; Smyth and Kahlmeter, 2005; Stoakes et al., 2006). The performance of 
MSA and all other selective media as well, may depend on several things. Differences in study 
designs may influence sensitivity and specificity; for example, some study designs test media only 
with pure cultures (Diederen et al., 2006; Kampf et al., 1998) while others plate swabs on several 
media in random (Apfalter et al., 2002) or pre-selected order (Louie et al., 2006). In addition, the 
salt-tolerance or antimicrobial susceptibility of a locally prevalent MRSA strain may also influence 
performance (Jones et al., 1997; Merlino et al., 2002b). 
One of the most commonly used commercial selective media, Oxacillin Resistance Screening Agar 
Base (ORSAB, Hampshire, England), contains mannitol and aniline blue for the detection of 
mannitol fermentation, which indicates S. aureus growth. A high concentration of salt and lithium 
chloride should suppress non-staphylococcal growth, oxacillin inhibits MSSA, and polymyxin B 
inhibits other bacteria able to grow in such a high salt concentration. The sensitivity and specificity 
of ORSAB performed directly from clinical specimens for the detection of MRSA appear in Table 
1. Further incubation for up to 48 h increased sensitivity, but specificity decreased. Recently, 
researchers have developed and evaluated a few other selective, commercial chromogenic media for 
accurate “next-day” detection of MRSA. Chromagar MRSA contains cefoxitin as a selective 
antibiotic, and due to a growth of MRSA, chromogenic substrate is hydrolyzed and mauve colonies 
form. In MRSA ID, MRSA forms green colonies due to the production of alpha glucosidase. The 
media also contain cefoxitin as a selective agent. A third cefoxitin-supplemented chromogenic agar, 
MRSA Select, also forms mauve colonies due to the growth of MRSA. The sensitivities and 
specificities of Chromagar MRSA, MRSA ID, and MRSA Select for detecting MRSA directly from 
patient specimens appear in Table 1. Reports indicate that at 48 h, these chromogenic media are less 
specific, although the sensitivity improved. The application of a cefoxitin disk on a chromogenic 
medium with no antibiotic has also been reported to be an attractive, alternative method of 
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screening for MRSA (Hedin and Fang, 2005). Based on the published data (Table 1), MRSA Select 
seems to be superior for MRSA screening. Care must be taken, however, in interpreting the data on 
sensitivity and specificity of screening media in comparative studies, because the reported 
performance of any medium will depend on the comparators. Hence, a medium that performs well 
in one study might appear less effective in another. 
Enrichment media are commonly used to improve sensitivity by allowing the specimens to grow 
during the incubation time, usually overnight, before plating on solid media. Enrichment broths 
usually contain a high concentration of NaCl, 6.5% or 7.5%, recommended by the American 
Society for Microbiology (Isenberg, 2004), and may contain oxacillin, methicillin, cefoxitin, or 
ciprofloxacin or other non-beta-lactam antibiotics to add selectivity. However, high salt-containing 
enrichment broth has been reported to inhibit the growth of endemic MRSA strains. According to 
two studies, the optimal salt concentration for MRSA screening should not exceed 2.5% NaCl 
(Bruins et al., 2007; Jones et al., 1997), although this concentration is too low to sufficiently inhibit 
contaminating flora (Van Enk and Thompson, 1992). Moreover, the enrichment step introduces a 
delay for MRSA detection. Indicator enrichment media containing carbohydrate, indicator, and 
antibiotics, may be useful for detecting growth without a subculture. All the negative broths can be 
discarded if the sensitivity is good, while confirmatory tests are performed on isolates from only the 
positive broths. The use of the commercial indicator enrichment medium evaluated thus far has 
shown a sensitivity of 85%, but a specificity of only 43.6% (Gurran et al., 2002).  
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Table 1. Solid agar media used for MRSA detection in clinical specimens.
Sensitivity (%) 
after 
incubation for 
Specificity 
(%) after 
incubation 
for 
Medium 
(Abbreviation) 
Total 
MRSA 
isolates/no. 
of samples 
Specimens 
from (no.) 
Comparator media or 
tests 
24 h 48 h  24 h 48 h 
Reference 
Oxacillin 
Resistance 
Screening Agar 
(ORSAB) 
104/455 
nares (132) 
perineum (109) 
skin and soft 
tissue (206) 
sputum (5) 
urine (3) 
mannitol-salt agar with 
oxacillin 2mg/L 76.0 98.0 ND
a 89.7 (Simor et al., 2001) 
Oxacillin 
Resistance 
Screening Agar 
(ORSAB) 
236/579 
nares (131) 
axilla (119) 
inguinal (70) 
throat (60) 
anal (34) 
insertion sites of 
devises (24) 
other (80) 
Phenyl-mannitol-salt 
agar with oxacillin 1 
μg disk 
Columbia blood agar 
with 10 μg colistin disk 
50.8 68.2 95.6 94.5 (Apfalter et al., 2002) 
Oxacillin 
Resistance 
Screening Agar 
(ORSAB) 
85/747 
nose (192) 
throat (180) 
axillae (209) 
perineum (119) 
wounds (47) 
CHROMagar MRSA 
MRSA ID 62.0 78.0 97.9 93.1 
(Perry et al., 
2004) 
Oxacillin 
Resistance 
Screening Agar 
(ORSAB) 
30/366 
perineum (153) 
throat (116) 
nose (54) 
mouth (30) 
wounds (8) 
umbilical region 
(3)  
ear (2) 
CHROMagar MRSA 
MRSA ID 57 77 92 83 
(Compernol
le et al., 
2007) 
CHROMagar 
MRSA 85/747 
nose (192) 
throat (180) 
axillae (209) 
perineum (119) 
wounds (47) 
ORSAB 
MRSA ID 59.0 72.0 99.3 92.1 
(Perry et al., 
2004) 
CHROMagar 
MRSA 146/2015 nares (2015) Trypticase soy agar 82.2 95.2 99.7 99.7
b  (Flayhart et al., 2005) 
CHROMagar 
MRSA 111/2125 
nares (1243) 
perineal (882) 
MRSASelect
Mannitol-salt agar with 
6 mg/L oxacillin 
Mannitol-salt agar with 
cefoxitin 
74.8 82.9 99.1 NDa (Stoakes et al., 2006) 
CHROMagar 
MRSA 113/831 nares (831) 
Trypticase soy agar 
with blood 
Müller-Hinton agar 
with 10 mg/L 
tobramycin 
95.6 98.3 100 100 (Loulergue et al., 2006) 
CHROMagar 
MRSA 30/366 
perineum (153) 
throat (116) 
nose (54) 
mouth (30) 
wounds (8) 
umbilical region 
(3) 
ear (2) 
ORSAB 
MRSA ID 67 73 98 90 
(Compernol
le et al., 
2007) 
aND means not determined, or could be calculated according to data published. 
bBy excluding mauve colonies that were coagulase negative or in consistent with MRSA in Gram staining. 
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Table 1. (continued) 
Sensitivity (%) 
after 
incubation for 
Specificity 
(%) after 
incubation 
for 
Medium 
(Abbreviation) 
Total 
MRSA 
isolates/no. 
of samples 
Specimens from 
(no.) 
Comparator media or 
tests 
24 h 48 h  24 h 48 h 
Reference 
CHROMagar 
MRSA 78/205 
nose (101) 
groin (52) 
axilla (52) 
MRSA ID 
MRSASelect 
IDI-MRSA PCR test 
GenoType MRSA 
Direct -PCR test 
63 71 99 67 (van Hal et al., 2007) 
MRSA ID 85/747 
nose (192) 
throat (180) 
axillae (209) 
perineum (119) 
wounds (47) 
ORSAB 
CHROMagar MRSA 80.0 89.0 99.5 85.6 
(Perry et al., 
2004) 
MRSA ID 30/366 
perineum (153) 
throat (116) 
nose (54) 
mouth (30) 
wounds (8) 
umbilical region 
(3) 
ear (2) 
CHROMagar MRSA 
ORSAB 60 77 98 94 
(Compernol
le et al., 
2007) 
MRSA ID 78/205 
nose (101) 
groin (52) 
axilla (52) 
CHROMagar MRSA 
MRSASelect 
IDI-MRSA PCR test 
GenoType MRSA 
Direct -PCR test 
71 82 98 53 (van Hal et al., 2007) 
MRSASelect 111/2125 nares (1243) perineal (882) 
CHROMagar MRSA 
Mannitol-salt agar with 
6 mg/L oxacillin 
Mannitol-salt agar with 
cefoxitin 
97.3 NDa 99.8 NDa (Stoakes et al., 2006) 
MRSASelect 181/6199 
nares (2483) 
perianal (2312) 
catheter exit site 
(647) skin/soft 
tissue (632) 
sputum (58) 
urine (67) 
Mannitol-salt agar with 
8 mg/L cefoxitin 93.0 98.0 99.5 92.0 
(Louie et 
al., 2006) 
MRSASelect 78/205 
nose (101) 
groin (52) 
axilla (52) 
CHROMagar MRSA 
MRSA ID 
IDI-MRSA PCR test 
GenoType MRSA 
Direct -PCR test 
64 69 95 74 (van Hal et al., 2007) 
2.4.2 Identification of S. aureus  
S. aureus forms golden or white colonies on blood agar. All the strains produce catalase, an enzyme 
which converts hydrogen peroxide (H2O2) to water and oxygen. The catalase test is useful to 
distinguish staphylococci from enterococci and streptococci. Most of these strains ferment mannitol 
and trehalose anaerobically which, among other tests, may serve to identify S. aureus. S. aureus is 
able to clot extracellular plasma, and can thereby be differentiated from most other staphylococci 
(Bannerman, 2003). For routine testing, more rapid coagulase tests are used, especially commercial 
latex agglutination tests (Gupta et al., 1998; van Griethuysen et al., 2001). Early versions of these 
latex tests detected only fibrinogen binding protein (clumping factor) and protein A on the cell 
21
surface of S. aureus, and problems arose with some MRSA strains (Kuusela et al., 1994). Later 
formulations of these tests also detected either capsular polysaccharide or other group-specific 
antigens, and are considered reasonably accurate, although none of these tests can correctly 
distinguish S. aureus from all other Staphylococcus isolates (Gupta et al., 1998; van Griethuysen et 
al., 2001). Deoxyribonuclease (DNase) plates can also serve to identify S. aureus, although some 
coagulase-negative staphylococci (CoNS) produce sufficient DNase to give positive results in 
DNase tests (Menzies, 1977). Several biochemical identification kits and automated systems are 
also available. Performances of these tests are reported to be good (Fonsale et al., 2004; Layer et al., 
2006; Ligozzi et al., 2002; Spanu et al., 2003), although most of them are technically time 
consuming or expensive. Molecular tests are sometimes needed to confirm the identity of S. aureus. 
The DNA probe test for S. aureus-specific 16S rRNA yields results of S. aureus or non-S. aureus.
This rapid test has served as a reference method for other commercial rapid tests when identifying 
S. aureus directly from blood cultures (Chapin and Musgnug, 2003). Most molecular methods are 
still PCR based, and a range of primers designed to amplify S. aureus-specific targets have been 
developed. Genes such as nuc (nuclease), 16S rRNA, coa (coagulase), clfA (clumping factor), and 
femA can distinguish S. aureus from other staphylococci, but S. aureus-specific molecular tests are 
usually combined with the simultaneous detection of mecA, thus enabling the identification of 
MRSA isolates (Brakstad et al., 1993; Geha et al., 1994; Kearns et al., 1999; Mason et al., 2001; 
Vannuffel et al., 1995).  
2.4.3 Phenotypic detection of methicillin resistance in S. aureus
In assessing the performance of antimicrobial susceptibility testing methods, the minimum 
inhibitory concentration (MIC) determined by a dilution method has traditionally been the reference 
method. The Etest method (AB Biodisk, Solna, Sweden) also provides a MIC result, and is simpler 
to perform than the dilution method. The disk diffusion method is, however, the most widely used 
method for confirming methicillin resistance in clinical microbiology laboratories. For PBP2a 
detection, a rapid and commercially available latex agglutination test is commonly used (Nakatomi 
and Sugiyama, 1998). In this method, PBP2a is extracted from a suspension of colonies and 
detected by agglutination with latex particles coated with monoclonal antibodies to PBP2a. 
Automated methods include tests for methicillin and oxacillin susceptibility and are generally 
considered reliable for S. aureus, although a few incorrect results have been reported (Frebourg et 
al., 1998; Kampf et al., 1999; Ligozzi et al., 2002; Ribeiro et al., 1999). The Clinical and Laboratory 
Standard Institute (CLSI, formerly NCCLS; USA) is a leading committee which recommends 
standards for antimicrobial susceptibility testing for global application, and the Finnish national 
laboratory guidelines on antimicrobial susceptibility testing (FiRe-standard) follow those of the 
CLSI. 
Several conditions used in phenotypic in-vitro laboratory tests, including medium, inoculum, 
incubation time and temperature, and test agent, are known to affect the expression of resistance 
(Brown, 2001; Sutherland and Rolinson, 1964). MRSA is reportedly more clearly distinguished on 
Müller-Hinton (MH) agar than on Iso-Sensitest, Diagnostics Sensitivity Test (DST), and PDM 
media (Brown and Kothari, 1974; Monsen et al., 2003), although researchers have reported 
variation in methicillin susceptibility test performance with MH medium from different 
manufacturers (Hindler and Inderlied, 1985; Mackenzie et al., 1995) and between different batches 
of MH medium from a single manufacturer (Coombs et al., 1996). CLSI has recommended the 
addition of 2% NaCl to MH only in the dilution method (CLSI, 2006), while the British Society for 
Antimicrobial Chemotherapy (BSAC) recommends the addition of salt for both dilution and disk 
diffusion methods (BSAC, 1998). Inoculum density is also an important factor for expressing 
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resistance. A larger inoculum increases the likelihood of detecting the heterogeneously resistant cell 
population, but a heavy inoculum together with an increased concentration of NaCl may also lead to 
increased false-resistant reports (Huang et al., 1993). Lowering the incubation temperature to 30°C 
(Merlino et al., 2002b), and extending the incubation time to 48 h (Brown, 2001) may improve the 
reliability of detection. The test agent has traditionally been methicillin or oxacillin. Recently, 
cefoxitin disk diffusion test has been recommended for the reliable detection of methicillin 
resistance (Cauwelier et al., 2004; CLSI, 2006; Felten et al., 2002; Skov et al., 2003; Skov et al., 
2006; Swenson and Tenover, 2005). Cephamycins, including cefoxitin, have a high affinity for S. 
aureus PBP4, a protein involved in cell wall cross-linking. Previous experiments showed a 
relationship between PBP2, PBP4, and methicillin resistance (Murakami et al., 1987). Cefoxitin is 
assumed to be a better inducer of mecA gene expression than is oxacillin or methicillin, and thus, is 
better for screening heterogeneous MRSA populations expressing the mecA variable. The major 
advantage of cefoxitin is that the optimum test conditions are similar to those used in the 
susceptibility testing of other antibiotics (Skov et al., 2006).  
2.4.4 Verification of MRSA with in-house molecular methods 
PCR-based methods have been used routinely by reference laboratories as the standard method for 
detecting and verifying MRSA. Primers for the amplification of the mecA gene and S. aureus-
specific gene loci such as nuc, 16S rRNA, coa, clfA, femA, and femB, have served that purpose 
(Brakstad et al., 1993; Geha et al., 1994; Kearns et al., 1999; Kobayashi et al., 1994; Mason et al., 
2001; Vannuffel et al., 1995). A number of studies have examined the use of molecular methods for 
the direct detection of MRSA in positive blood cultures, including gel-based PCR (Louie et al., 
2002; Maes et al., 2002) and real-time PCR (Shrestha et al., 2002; Tan et al., 2001). The detection 
of MRSA direct from non-sterile sites such as the nostrils, the throat, wounds and the perineum is in 
great demand. The development of such methods is more complex because the mecA gene is highly 
conserved among staphylococci, and primers used to detect S. aureus and mecA will give MRSA 
positive results when tested on a mixed culture containing an MSSA and a methicillin-resistant 
CoNS. Many strategies have been directed to reduce false positives. The use of MRSA-selective 
enrichment broth prior to duplex PCR for mecA and femB (Jonas et al., 2002), and prior to nuc gene 
amplification followed by use of mecA and nuc primers for those samples which were detected as 
nuc positive after the enrichment step by real-time PCRs (Fang and Hedin, 2003), has been 
developed and evaluated. In addition, an isothermal signal amplification method (CytAMP) has 
been applied to the detection of MRSA from screening swabs (Levi et al., 2003). This assay 
simultaneously targets coa and mecA genes, and the results were obtained as a colour signal on a 
96-well microtiter plate within 3 h following overnight enrichment in the selective broth. Since all 
of these strategies require an enrichment step, neither of them can be used for same-day MRSA 
reporting. A rapid MRSA detection assay, which consists of an immunomagnetic enrichment step, 
first used to selectively capture S. aureus using an antibody to protein A, followed by the extraction 
of immunocaptured bacterial DNA and their identification by a triplex quantitative PCR for mecA, 
S. aureus femA, and CoNS femA genes (Francois et al., 2003). This assay enables the detection and 
identification of MRSA in less than 6 h after sample collection.  
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2.4.5 Commercial applications for MRSA verification
Commercial PCR-based assay GenoType® MRSA (Hain Lifescience, Germany) is a rapid, 3-h 
method enabling the detection of the S. aureus, Staphylococcus epidermidis, and mecA gene. The 
assay involves rapid DNA isolation and PCR amplification, followed by hybridization using 
specific oligonucleotide probes immobilized onto a membrane (Cuny et al., 2001). Special 
equipment for agarose gel electrophoresis and waste treatment for ethidium bromide is unnecessary 
with this assay. The EVIGENETM MRSA Detection (AdvanDx, Inc, Woburn, MA; For Research 
Use Only) kit is a rapid (3-h), non-PCR assay, which detects mecA and nuc genes by colorimetric 
gene probe hybridization in a microwell strip format (Skov et al., 1999; Smyth et al., 2001). Both of 
these methods, however, require a pure culture for the detection of MRSA.  
Tests detecting MRSA directly from blood cultures are also available as commercial applications. 
GenoType® BC Gram-positive (Hain Lifescience, Germany) enables the detection of S. aureus
among 16 other gram-positive bacterial species and its resistance to methicillin and vancomycin 
within a few hours, according to the manufacturer, and in conjunction with a 3-h enrichment step 
for the use of the EVIGENETM MRSA Detection kit, will provide the results within seven hours 
(Levi and Towner, 2003; Poulsen et al., 2003). There are a few recently developed commercial 
assays available which may detect MRSA directly from non-sterile sites and enable same-day 
reporting (Table 2). BacLite® Rapid MRSA (Bio-Stat Diagnostic System, UK) was developed to 
detect ciprofloxacin-resistant MRSA strains directly from nasal swabs, and measures the activity, 
detected by a bioluminescence system, of adenylate kinase, an essential house-keeping enzyme. The 
test involves selective broth enrichment, magnetic microparticle extraction, and the selective lysis 
of S. aureus to add target organism specificity, and the results are available within five hours. 
GenoType® MRSA Direct (Hain Lifescience, Germany) is a 4- to 6-h test for clinical swabs 
involving DNA extraction and PCR amplification followed by the hybridization of oligonucleotide 
probes onto a membrane, and detection by staining. This assay uses primers for orfX and one primer 
pare for a unique region of SCCmec. IDI-MRSATM (Infectio diagnostic Ste-Foy, Quebec) is a 1- to 
2-h assay involving the extraction of DNA directly from clinical nasal swabs followed by one-step 
real-time PCR. For amplification, five forward primers targeting the SCCmec right extremity 
regions (SRE) corresponding to SCCmec types I, II, III, IVa, IVb, and IVc are combined with one 
reverse primer and three molecular beacons specific to the orfX region (Huletsky et al., 2004). False 
negative results may be due to a polymorphism of SRE, since the assay has limited numbers of 
primers for SRE. In addition, some MRSA strains may lose the mecA gene while maintaining 
fragments of the SCCmec gene, thus resulting in false positive results (Donnio et al., 2005).  
The relative sensitivities and specificities of the IDI-MRSATM and GenoType® MRSA Direct assays 
have been compared and according to these studies, the IDI-MRSATM seemed to have better 
performance (Francois et al., 2007; van Hal et al., 2007) and is more cost-effective (van Hal et al., 
2007). One possible reasons for the lower sensitivity of GenoType® MRSA Direct than that of IDI-
MRSATM may be related to the difference in the detection limits of the assays: with IDI-MRSATM, 
detection limit is 25 CFU per nasal swab, and with GenoType® MRSA Direct, 30 CFU per 5 μl. 
Since each IDI-MRSATM run could be completed in 2 h with a Smart Cycler DNA amplification 
system containing 16 random access reaction places, 64 specimens could be detected within 
working hours a day (reaction places for positive and negative controls are needed in each run). The 
GenoType® MRSA Direct assay run takes 4-6 h to obtain final results, and thus, using 12-places 
incubator (TwinCubator®) at most 24 specimens could be detected a day. In 2007, the XpertTM
MRSA system from the same manufacturer than IDI-MRSATM came to the market. Thus far, it is 
the only available system that combines sample preparation with real-time PCR amplification and 
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detection for fully integrated and automated nucleic acid analysis. The system enables users to 
perform up to 16 different molecular tests concurrently in an hour. Hence, with the XpertTM MRSA 
system, total of 128 specimens could be detected a day. Sensitivity, specificity, positive predictive 
value, and negative predictive value of the assay of 86.3%, 94.9%, 84.5%, and 96.9%, respectively, 
has been reported by the manufacturer. 
Table 2. Evaluated commercial tests for MRSA screening directly from clinical specimens.
Test 
Total 
MRSA 
isolates/no. 
of samples 
Specimens 
from (no.) 
Comparator 
test 
Sensitivi-
ty, %
Specifici-
ty, %
Positive 
predicti-
ve value, 
% 
Negative 
predicti-
ve value, 
% 
Reference 
BacLite®
Rapid 
MRSA 
157/1382 nostrils (1382) 
culture with 
mannitol-salt 
agar 
90.4 95.7 72.8 98.7 (Johnson et al., 2006) 
GenoType®
MRSA 
Direct 
37/508 
nose (209) 
throat (101) 
skin (80) 
groin (46) 
axilla (12) 
wound (34) 
other (26) 
enrichment 
culture with 
thioglycolate 
broth, 
culture with 
Columbia-
CNA-agar 
supplemented 
with colistin 
and nalidixic 
acid 
94.6 98.7 85.4 99.6 
(Holfelder 
et al., 
2006) 
GenoType®
MRSA 
Direct 
93/182 
strain 
collection 
of clinical 
isolates: 
MRSA (93) 
MSSA (89) 
culture (not 
specified), 
conventional 
PCR, IDI-
MRSATM
67 a
90b
57a
53b  
61a
66b
63a
84b
(Francois et 
al., 2007) 
GenoType®
MRSA 
Direct 
78/205 
nose (101) 
groin (52) 
axilla (52) 
culture with 
CHROMagar 
MRSA, 
MRSA ID, 
and 
MRSASelect, 
IDI-MRSATM
69 96 92 82 (van Hal et al., 2007) 
IDI-
MRSATM 72/288 
nostrils 
(288) 
culture with 
mannitol-salt 
agar,  
enrichment 
culture with 
tryptic soy 
broth   
91.7 93.5 82.5 97.1 (Warren et al., 2004) 
IDI-
MRSATM 81/331 
nostrils 
(331) 
culture with 
mannitol-salt 
agar 
100 98.4 95.3 100 
(Huletsky 
et al., 
2005) 
aPositive signal was recorded only for bands showing intensities higher that of the control  
bPositive results were recorded onto the strip for any band corresponding to the MRSA location, whatever its intensity 
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Table 2. (continued) 
Test 
Total 
MRSA 
isolates/no. 
of samples 
Specimens 
from (no.) 
Comparator 
test 
Sensitivi-
ty, %
Specifici-
ty, %
Positive 
predicti-
ve value, 
% 
Negative 
predicti-
ve value, 
% 
Reference 
IDI-
MRSATM 74/287 
pooled 
nasal and 
rectal 
swabs 
(174) 
nasal (53) 
rectal (28) 
other (32) 
enrichment 
culture with 
brain heart 
infusion 
broth 
supplemented 
with 5 mg/L 
aztreonam 
and 75 mg/L 
ceftizoxime 
96 96 90 98 (Desjardins et al., 2006) 
IDI-
MRSATM 93/182 
strain 
collection 
of clinical 
isolates: 
MRSA 
(93) 
MSSA (89) 
culture (not 
specified), 
conventional 
PCR, 
GenoType®
MRSA 
Direct 
94 64 71 92 (Francois et al., 2007) 
IDI-
MRSATM 100/997 
nose (522) 
throat 
(212) 
perineum 
(206) 
skin 
wounds 
(60) 
culture with 
MRSA-ID, 
enrichment 
culture with 
brain heart 
infusion 
broth 
81.0 97.0 75.0 97.9 (de San et al., 2007) 
IDI-
MRSATM 78/205 
nose (101) 
groin (52) 
axilla (52) 
culture with 
CHROMagar 
MRSA, 
MRSA ID, 
and 
MRSASelect, 
GenoType®
MRSA 
Direct 
90 96 93 94 (van Hal et al., 2007) 
2.5 Evolution of MRSA 
2.5.1 Methods for investigating the evolution of MRSA 
Monitoring the spread of MRSA strains requires efficient and accurate epidemiologic typing 
systems that allow the recognition of isolates originated from a common ancestor and the 
discrimination between unrelated isolates. An optimal typing method should show high typeability 
(i.e. referring to the ability of the test to provide unambiguous results for each isolate examined), 
high reproducibility (i.e. referring to the ability of the technique to produce the same result with 
repeated tests), high discriminatory power, and stability. In addition, ease of use and ease of 
interpretation, rapidity, and low cost may also be criteria affecting the choice of method (Struelens, 
1996; van Belkum et al., 2001).  
26
Phenotypic methods such as phage typing and antimicrobial susceptibility testing have long been 
used for the discrimination of MRSA strains (Parker, 1972; Rossney et al., 1994). Phage typing is 
based on lysis to a standard set of phage. Antimicrobial susceptibility testing usually produces the 
first typing results available, and may therefore be useful in short outbreaks caused by multiresistant 
strains. Phenotypic typing methods, however, do not directly characterize the expression of 
different genes, thus environmental factors such as the antimicrobial treatment of the host may have 
an influence on bacterial phenotype. In addition, genetically distinct strains may share a common 
resistance pattern, especially multiresistant MRSA clones. However, due to the limited 
reproducibility and lack of typeability or discriminatory power of some of these methods, they are 
inadequate approaches for bacterial comparisons. 
Genotypic typing methods are based on the analysis of chromosomal or extrachromosomal DNA. 
Plasmid analysis was the first DNA-based method to be applied to S. aureus, and has served in 
several outbreak investigations (Archer and Mayhall, 1983; Hartstein et al., 1989). However, the 
reproducibility of the method has been shown to be only moderate (Tenover et al., 1994), and the 
relative stability of staphylococcal plasmids has been debated. Restriction fragment length 
polymorphism (RFLP) with a variety of DNA and RNA probes has also been used to type bacterial 
strains, thus providing a discriminative fingerprint of the entire chromosome. In this method, 
chromosomal DNA is restricted by frequently cutting enzymes, followed by agarose gel 
electrophoresis, Southern blotting (transferring the DNA fragments from the agarose gel to a nylon 
membrane), and hybridization with specific probes. Ribotyping is the most widely used adequate 
procedure of this technique (Blumberg et al., 1992), but it has shown low discriminatory power 
(Tenover et al., 1994). In addition, several polymerase chain reaction (PCR) -based methods have 
been developed. In those methods, specific genes with variable repeat regions, such as coa and spa
(Frenay et al., 1994; Hoefnagels-Schuermans et al., 1997; Tenover et al., 1994) or polymorphic 
non-coding repetitive sequences dispersed around bacterial genomes, serve as targets for PCR 
amplification (Del Vecchio et al., 1995).   
SCCmec-typing is used for amplifying the ccr and mec gene complexes (Okuma et al., 2002). 
Multiplex-PCR strategies have been developed to distinguish between SCCmec types I-IV and 
some of its variants (IA, IIIA, and IIIB) (Oliveira and de Lencastre, 2002), and more recently, 
SCCmec types and subtypes I, II, III, IVa, IVb, IVc, IVd, and V (Zhang et al., 2005). Neither of 
these methods, however, discriminate between the seven variants (IIA, IIB, IIC, IID, IIE, IVE, IVF) 
recently described (Shore et al., 2005). The discrimination power is low in SCCmec-typing, since 
only five major SCCmec types have been recognized thus far. SCCmec types may still be important 
in epidemiological studies. 
Pulsed-field gel electrophoresis (PFGE) has been the most commonly used genotyping method for 
MRSA outbreak investigation and has been regarded as the gold standard method (Roberts et al., 
1998; Struelens et al., 1993; Tenover et al., 1994). PFGE was introduced in 1984 (Schwartz and 
Cantor, 1984) and is based on RFLP banding patterns on agarose gels obtained by the digestion of 
chromosomal DNA by rare-cutting restriction enzymes, usually SmaI. This digestion generates 
fragments 20-800kb in size separated by an apparatus that switches the direction of the current 
according to a predetermined pattern. Random genetic events, including point mutations and 
insertions and deletions of DNA, usually alter the PFGE pattern during the course of an outbreak. 
The interpretation of DNA fragment patterns generated by PFGE can be assigned to one of four 
categories: 1) indistinguishable from the outbreak pattern, 2) closely related to the outbreak pattern, 
3) possibly related to the outbreakpattern, or 4) unrelated to the outbreak pattern (Tenover et al., 
1995). Comparison of restriction patterns may, however, be subjective due to the large number of 
fragments. In addition, PFGE is a time-consuming and laborious method, and its applicability to 
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evolutionary analysis is limited. Moreover, the quality of gel patterns varies, rendering the 
comparison of strain analyses between laboratories difficult. Recently, PFGE protocols have been 
harmonized in an attempt to avoid this problem (Murchan et al., 2003).  
Multilocus sequence typing (MLST) is based on the sequencing of seven genes in the bacterial 
chromosome that are thought to be conservative. MLST has been developed for the identification of 
the hypervirulent lineages of Neisseria meningitidis, and has also served in investigating 
hypervirulence and antibiotic resistance among Streptococcus pneumoniae (Enright et al., 1999; 
Enright and Spratt, 1998; Maiden et al., 1998; Shi et al., 1998). Seven housekeeping genes (genes 
which are expressed in all cells and which code for molecules that are necessary for basic 
maintenance and essential cellular functions) chosen in a scheme of S. aureus, named arc
(carbamate kinase), aroE (shikimate dehydrogenase), glpF (glycerol kinase), gmk (guanylate 
kinase), pta (phosphate acetyltransferase), tpi (triosephosphate isomerase), and yqiL (acetyl 
coenzyme A acetyltransferase), are widely separated around the genome, thereby minimizing the 
impact of recent DNA exchange (Enright et al., 2000). Isolates are defined by the alleles present at 
the seven loci, each of which receives numbers from various databases that are then combined with 
a seven-digit allelic profile. Each unique allelic profile is assigned as an ST (sequence type) and 
compared to other isolates online (http://www.mlst.net). Isolates with the same ST are considered 
members of a single clone. As a technique, however, MLST is expensive and laborious, and thus 
may be unsuitable for routine typing. eBURST (Based Upon Related Sequence Typing) is an 
algorithm used to illustrate the genetic relationship between large MLST datasets that bear some 
pre-defined level of similarity between allelic profiles, and to predict the ancestral genotype of each 
group. A dataset of ST numbers and allelic profiles are entered into the BURST program 
(http://www.mlst.net/BURST/burst.htm), which then sub-divides isolates sharing high genetic 
similarity into clonal complexes (CCs) (Feil et al., 2004).  
In spa-typing, a polymorphic X-region of protein A is sequenced, and clustering of clonal 
complexes of related spa types are analyzed with an Internet-based tool 
(http://www.ridom.de/spaserver/) (Harmsen et al., 2003). The discriminatory power and 
concordance of spa typing has been reported to exist between PFGE and MLST (Hallin et al., 2007; 
Strommenger et al., 2006). 
2.5.2 Evolutionary history of MRSA  
Genetic evolutionary studies have demonstrated that MRSA has a largely clonal structure due to the 
low frequency of recombination between Staphylococcus. Investigators have suggested that point 
mutations are 15 times more likely to occur than recombination (Feil et al., 2003). Molecular typing 
techniques have disproved a theory proposed earlier that S. aureus acquired the mecA gene only 
once (Enright et al., 2002). Researchers have predicted that the extant ancestral MRSA is derived 
from MSSA by the acquisition of SCCmec type I and a single point mutation in one of the seven 
housekeeping genes (Enright et al., 2002; Robinson and Enright, 2003). The mecA gene has been 
shown to transfer into MSSA at least 20 times, since only a few successful phylogenetically distinct 
lineages have been found worldwide (Crisostomo et al., 2001; Deresinski, 2005; Enright et al., 
2002; Oliveira et al., 2002; Robinson and Enright, 2003). The creation of an international 
surveillance system with harmonized methodologies was required to aid in hospital infection 
prevention and control. CEM/NET (The Center for Molecular Epidemiology and International 
Network) was created in 1995 to detect the reservoirs of major Gram-positive pathogen clones 
(Aires de Sousa and de Lencastre, 2004), and the HARMONY network was established as a 
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collection of European epidemic and other important MRSA strains and developed a standardized 
PFGE protocol (Murchan et al., 2003).  
The distinct pandemic lineages have been named Iberian, Brazilian, Hungarian, New York/Japan, 
Pediatric, and EMRSA-16 clones, and the identification of clones was based primarily on a 
combination of PFGE, PCR-based techniques such as RAPD, Southern hybridization analysis such 
as ribotyping, and plasmid analysis (Aires de Sousa and de Lencastre, 2004). The Iberian clone 
caused a massive outbreak in 1989 in a Spanish hospital, where it was first identified (Oliveira et 
al., 2001). However, it seemed already to have existed in Belgium and France as early as in 1984 
(Deplano et al., 2000). Subsequently, the Iberian clone was detected in many other European 
countries and in a hospital in New York (Krzyszton-Russjan et al., 2002; Murchan et al., 2003; 
Oliveira et al., 2001; Salmenlinna et al., 2002). In Finland, the clone (FIN-1) was first detected in 
the western part of the country in 1991 (Salmenlinna et al., 2000). The Brazilian clone was widely 
disseminated in Brazilian hospitals and has spread to other countries in South America (Aires de 
Sousa et al., 2001; Oliveira et al., 2001; Teixeira et al., 1995). It was also found in many countries 
in Europe (Aires de Sousa and de Lencastre, 2003; Enright et al., 2002), and was first isolated in 
Central Finland in 1992 (FIN-2) (Salmenlinna et al., 2002). The Hungarian clone has been widely 
spread in Hungarian hospitals since 1993 (Oliveira et al., 2001), and was also found to be the major 
clone in Taiwan and China in 1998-1999 (Aires de Sousa et al., 2003). The Hungarian clone (FIN-
2c and FIN-13) was detected in Southern and Western Finland since 1998, but only 13 isolates have 
been found thus far (unpublished data). The New York/Japan clone was detected as the major clone 
in the USA, in many hospitals across Canada, in Tokyo, and in many countries in Europe (Aires de 
Sousa et al., 2000; Enright et al., 2002; McDougal et al., 2003; Oliveira et al., 2001; Simor et al., 
2002). In Finland, the New York/Japan clone (FIN-3) was first detected in 1992 in Southern 
Finland (Salmenlinna et al., 2000). The Pediatric clone was reported for the first time in 1991 in a 
pediatric hospital in Portugal (Oliveira et al., 2001). Afterwards it was found in several regions in 
Europe, the USA, and Latin America (Aires de Sousa et al., 1998; Enright et al., 2002; Gomes et al., 
2001; Oliveira et al., 2001). The representative strain (FIN-8) of the Pediatric clone was found in 
1994 in Southern Finland (Salmenlinna et al., 2000), but since then the clone seems to have 
disappeared (unpublished). UK EMRSA-16 is one of the major clones found in UK hospitals 
(Moore and Lindsay, 2002), and has disseminated throughout many regions in Europe, Mexico, and 
Canada (Aires de Sousa et al., 2001; Murchan et al., 2003; Simor et al., 2002). In Finland, UK 
EMRSA-16 (FIN-5a) was first detected in 1995 (Salmenlinna et al., 2000), and was found only in 
persons having had hospital contact (Salmenlinna et al., 2002). In addition to these six major clones, 
studies have described several other MRSA clones, such as UK EMRSA-15, Berlin, Hannover, 
South German, Irish-1, and UK EMRSA-1, -2, -3, -4, -5, -6, -7, -10, -11, 12, -13, -14, and -17 
(Enright et al., 2002; Witte, 1999). 
MLST has, however, revealed that several MRSA clones considered distinct with PFGE and other 
molecular typing techniques were, in fact, indistinguishable (Enright et al., 2002) (Table 3). For 
example, of the major pandemic clones, the Brazilian and Hungarian clones showed ST239, and the 
New York/Japan and Pediatric clones showed ST5, whereas of the minor clones EMRSA-2, -6, -7, -
12, -13, -14 and the Irish-1 clones showed ST8. Using MLST and eBURST, the five most common 
pandemic MRSA lineages can be visualized as clonal complexes: CC5, CC8, CC22, CC30, and 
CC45 (Enright et al., 2002). All of these lineages have acquired SCCmec several times, with the 
possible exception of CC22. Thus, some clones may differ in SCCmec though they possess 
identical ST. For example, the Brazilian clone possesses SCCmec type IIIA whereas the Hungarian 
clones possess SCCmec type III, and the New York/Japan clones possess SCCmec II whereas 
Pediatric clones possess SCCmec type IV. Nowadays, MLST is wide-spread among research and 
diagnostic laboratories, enabling comparison of the results obtained in different laboratories via the 
29
Internet. SCCmec typing has recently been combined with MLST for MRSA typing, and therefore, 
MRSA findings reported in epidemiological studies are usually defined by both their sequence type 
(ST) and their SCCmec type, for example ST5-II. 
Table 3. The most common pandemic MRSA lineages and their distribution. The most common names of the major 
clones appear in bold. The data were collected from the references in the text. 
  
Clonal Complex 
(CC) Common name of clone 
Sequence type of 
MLST and the 
most common 
SCCmec type 
Data reported (for example): 
New York/Japan, USA100, 
CMRSA-2 ST5-II Finland, Canada, Ireland, Japan, USA 
Pediatric, USA800 ST5-IV Argentina, Colombia, Finland, France, Poland, Portugal, UK, USA 
UK EMRSA-3 ST5-I Poland, Slovenia 
CC5 
Southern Germany, Rome ST228-I Finland, Germany, Slovenia, Italy  
UK EMRSA-2, -6, USA300, 
USA500 ST8-IV Finland, France, USA 
Irish, USA500 ST8-II Ireland, UK, USA 
Brazilian, Portugese, Vienna, 
Asia, UK EMRSA-1, -4, -11,
CMRSA-3, Hungarian 
ST239-III 
Argentina, Brazil, Canada, Chile, China, Czech 
Republic, Finland, Germany, Greece, Ireland, 
Netherlands, Poland, Portugal, Slovenia, Sweden, 
Taiwan, UK, Uruguay, USA 
Iberian, UK EMRSA-5, -7 ST247-I 
Belgium, Czech Republic, Finland, France, 
Germany, Italy, Netherlands, Poland, Portugal, 
Slovenia, Spain, Sweden, UK, USA 
Hannover, UK EMRSA-10 ST254-IV Germany, UK 
CC8 
Archaic (first) MRSA, UK 
EMRSA-8 ST250-I 
Denmark, Germany, Switzerland, Uganda, UK, 
USA 
CC22 UK EMRSA-15, Barnim ST22-IV Finland, Germany, Ireland, Sweden, UK 
CC30 UK EMRSA-16, USA200, CMRSA-4 ST36-II 
Belgium, Canada, Denmark, Finland, Greece, 
Mexico, Sweden, Switzerland, UK, USA 
Berlin, USA600 ST45-IV Belgium, Germany, Finland, Sweden, USA 
CC45 
USA600, CMRSA-1 ST45-II Canada, USA 
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3. AIMS OF THE STUDY 
The purpose of this study was to investigate recent trends in the epidemiology and molecular 
epidemiology of MRSA in Finland with constantly increasing numbers of MRSA. The methods 
used in screening for S. aureus/MRSA, and the phenotypic and genotypic methods used to detect 
MRSA were evaluated.  
The specific aims of this study were 
1. To analyse the data on MRSA cases notified to the NIDR and antibiotic resistance profiles of 
MRSA isolates, to assess the situation in LTFs, and to review the methods used in laboratory 
diagnostics in Finland.  
2. To examine the molecular epidemiology of MRSA in Finland in comparison to European and 
pandemic MRSA clones by using the nationwide collection of MRSA strains and to analyze the 
background information of MRSA-positive persons. 
3. To perform a point-prevalence survey in a LTF after the outbreak of an MRSA strain not 
previously encountered in Finland, to assess the molecular epidemiology of MRSA and MSSA 
strains and to compare the results to the national strain collection, and to perform MRSA screening 
to detect low-level oxacillin-resistant isolates.  
4. To assess the rate of MSSA and MRSA colonization in the largest NH in the Helsinki 
metropolitan area as well as the role of screening sites along with broth enrichment culture on 
sensitivity to detect S. aureus. 
5. To compare phenotypic disk diffusion and MIC methods with two agents for MRSA screening, 
and to compare genotypic in-house PCR methods to commercial genotypic methods for verifying 
MRSA.  
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4. MATERIAL AND METHODS  
A short summary of the materials and methods used in the separate studies is presented in Table 4. 
Table 4. Specimens, selection criteria, and methods used in the study. The text contains a more detailed description. 
Study Specimens Selection criteria (number of specimens or isolates studied) Methods used
a
I Isolated strains 
All MRSA isolates in Finland from 
the years 1997-2002, one per person 
(1718 [NIDR] and 1702 [NRL]) 
- Data analysis of antimicrobial 
susceptibilities from NRL 
- Data analysis of MRSA and invasive S. 
aureus cases from NIDR 
- Analysis of the methods for MRSA 
identification and screening activity at 
the national level with an emailed 
questionnaire –based survey 
- Analysis of the MRSA situation in 
nursing homes with a questionnaire –
based survey 
II Isolated strains 
All MRSA isolates in Finland from 
the years 1997-2004, one per person 
(4026 [NIDR] and 4091 [NRL]) 
- Data analysis of MRSA and invasive S. 
aureus cases from NIDR 
- Analysis of the background information 
on MRSA-positive persons 
- PFGE 
- MLST 
- SCCmec by in-house PCR 
- PVL by in-house PCR 
III 
Screening specimens 
from nostrils, skin 
lesions, and catheter 
urines 
From all long term facility residents 
present and volunteered in the 
Northern Finland (90 specimens, 30 
isolates) 
- Description of nursing home setting  
- Sampling 
- Culture of screening specimens 
- Conventional biochemical methods 
- Antimicrobial susceptibility 
- GenoType® MRSA test 
- PVL by GenoType® Staphyloccus test 
- PFGE 
- MLST 
- SCCmec by in-house PCR 
IV 
Screening specimens 
from nostrils, throat, 
perineum, skin 
lesions, catheter exit 
sites, and catheter 
urines  
From all nursing home residents 
present and volunteered in the 
Helsinki metropolitan area (663 
specimens, 165 isolates) 
- Description of nursing home setting 
- Sampling 
- Culture of screening specimens 
- Conventional microbiological methods 
- Antimicrobial susceptibility 
- GenoType® MRSA test 
- PFGE 
V Isolated strains, reference strains 
A: Consecutive isolates from March-
April 2004 (122) 
B: Control strains of S. aureus, 
including Finnish epidemic MRSA 
isolates (42) 
C: Control strains of other species 
and genera including clinical and 
screening isolations of 
Staphylococcus epidermidis, and 
reference strains of different CoNS 
and enterococci (62) 
- Antimicrobial susceptibility for A and B 
- In-house PCR for A and B  
- GenoType® MRSA-test for A, B and C 
- EVIGENETM MRSA Detection for A and 
B  
Studies I, II, and V include S. aureus identification, antimicrobial susceptibility testing, mecA verification by PCR, MLST and 
SCCmec typing with applicable parts in a routine typing scheme at the KTL: these methods, however, were not necessarily the 
methods used in the specific study.  
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4.1 National MRSA surveillance and bacterial strain collection (studies I, II, and V) 
Finnish clinical microbiology laboratories notify all MRSA isolations to the NIDR at the KTL. The 
date, source of specimen, and the patient’s birth date, gender, and health care institution are 
recorded. Only one notification per person is registered per 36-month period. In case of blood or 
cerebrospinal fluid (CSF) specimens, the time interval is three months. Studies I and II used NIDR 
data. Clinical microbiology laboratories send all MRSA isolates to the NRL at the KTL for 
verification of oxacillin-resistance and typing (see 4.4.4-4.4.5 and 4.5.1-4.5.3). The S. aureus
collection includes the Harmony collection (Murchan et al., 2003) in addition to all Finnish isolates 
sent by clinical microbiology laboratories. Studies I, II, and V used NRL data.  
In study V, a total of 226 bacterial isolates were studied, including 122 consecutive clinical S. 
aureus strains sent to the KTL for verification and typing in April-May 2004. Other S. aureus
isolates studied included 40 Finnish epidemic MRSA strains representing 24 different Sma I
macrorestriction patterns (Tenover et al., 1995), and 2 low-level oxacillin-resistant MRSA strains. 
Other species and genera used in this study included 40 clinical Staphylococcus epidermidis strains 
from invasive or other sites from the Helsinki University Hospital and from a LTF outside the 
Helsinki metropolitan area, 2 ATCC reference Staphylococcus epidermidis strains, 18 other ATCC 
staphylococcal reference strains, 1 Enterococcus faecalis isolated from the subclavia catheter, and 1 
E. faecium isolated from feces, both used as the reference strains in vancomycin-resistant 
enterococci (VRE) diagnostics in the NRL. One isolate per person was studied.  
4.2 Definitions and nomenclature of strains (studies I-V) 
In study I, multi-drug resistance (MDR) and non-multi-drug resistance (NMDR) were defined as 
three or more antibiotic groups other than beta-lactams, and two or fewer antibiotic groups, 
respectively, being ineffective against the MRSA strains according to CLSI (formerly NCCLS). 
Strain types were identified by PFGE (studies II-V), SCCmec typing (studies II and III), and MLST 
(studies II and III). PFGE served as the main method for typing, and one representative strain of 
each PFGE type was typed with SCCmec and MLST. Antibiotic resistance typing served as a 
supportive method along with molecular methods.  
Isolates differing by seven or more bands with PFGE were considered different types (sporadic), 
and those differing by one to six bands were considered subtypes (Tenover et al., 1995). The S. 
aureus PFGE database at the KTL serves as the basis for naming the isolates (after naming the 
isolates, they are called strains or strain types). The database includes all Finnish epidemic MRSA 
strains and the Harmony collection. If the PFGE profile represents a previously recognized 
Harmony collection profile, the isolate has been named accordingly. Otherwise, the name has been 
assigned based on the site of the outbreak or the name of the hospital. Since 2005, all MRSA strain 
names have become numeric. Subtypes are additionally labelled with letters. Sporadic strains were 
defined as those found from only one person during the study period 1997-2004. Outbreak/epidemic 
strains of MRSA were isolated from more than one person. For the analysis, only one strain per 
person was included, except with persons showing two or more different strains.  
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4.3 Epidemiological background information 
4.3.1 Questionnaire-based surveys (studies I and II) 
In study I, an email was sent to the largest clinical microbiology laboratories (n=23), which are 
members of the Finnish Study Group for Antimicrobial Resistance (FiRe), to ask about their MRSA 
screening methods. The questions on their laboratory methods included: 1) the composition of 
media used for antimicrobial susceptibility testing (MH or other), 2) the percentage of salt added, 3) 
the incubation temperature and time, 4) the usage of MRSA-selective agar media, 5) the usage of a 
latex agglutination test for detection of PBP2a, and 6) PCR-based detection of mecA-gene. To 
assess the screening activity of hospital districts, the number of MRSA cultures performed and the 
number of MRSA strains isolated in 2001 was also requested from the laboratories. 
The MRSA situation in long-term facilities in 2001 was assessed in study I with a questionnaire 
sent by email to the infection control nurses of each Finnish hospital district (n=21). The nurses 
were asked whether MRSA was found in patients or staff members of long-term facilities located in 
their hospital district. The types of long-term facilities involved and the number of MRSA findings 
were also inquired.  
In study II, additional background information from 2001 to 2003 were collected from persons who 
tested positive for MRSA by sending questionnaires to infection control nurses at relevant health 
care institutions. The information collected included 1) whether the MRSA positive person was a 
patient or a staff member; 2) whether the specimen was taken on clinical or screening basis; 3) 
whether the patient was screened because of a hospital contact abroad (hospitalization or surgery 
outside the Nordic countries in the six months prior to testing) or because of exposure to MRSA, 
and whether the staff member was screened because of a hospital contact abroad (worked outside 
the Nordic countries in the six months prior to testing) or because of an epidemic situation, and 4) 
whether the specimen was taken for another reason. 
4.3.2 Settings and outbreak in long-term facilities (studies III and IV) 
In study III, an MRSA outbreak in a 34-bed health care ward (HCW) and an associated 46-bed NH 
with 76 participating residents was described in a small municipality of 5000 inhabitants in 
Northern Finland. Patient transfers from the HCW to the nearby secondary care hospital occurred 
up to approximately twice per week, from the NH to the HCW, approximately 40 times per year, 
and to the secondary care hospital, between two to five times per year. Patients included mainly the 
elderly with multiple diseases. The first isolate of MRSA was found in a urine culture in a HCW in 
August 2003. The index patient was placed in a single room and cared for according to contact 
precautions. All three roommates were screened for MRSA. All in-patients of the HCW and NH 
were screened twice between October and November 2003, and once on 17 February 2004. The 
staff was not screened. A total of 255 screening specimens for MRSA were taken between August 
and December 2003; 12 new patients tested positive for MRSA, all from LTFs. In total, 726 clinical 
bacterial cultures were examined in the entire municipality in 2003. None tested positive for 
MRSA, except the urine culture of the index patient. A new PFGE profile (FIN-22) was obtained 
from all the 13 isolates of the different patients. The point-prevalence study was carried out on 26 
February 2004. Demographic data (age, sex, antimicrobials, foreign devices, and length of nursing 
stay) for each patient were collected and presented in the original publication.  
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Study IV was performed in the largest NH (25 wards with a total of 584 beds) in the Helsinki 
metropolitan area. In 2004, a total of 685 long-term residents (mean length of stay; 3.1 years) and 
420 short-term residents (approximately 1060 short-term nursing periods) were treated in the NH 
(annual occupancy; 99.3%). Of the residents, 76% were females with a mean age of 83 years, 62% 
of whom suffered from dementia. Of the 25 wards, 9 were selected based on the following criteria: 
1) at least one of the residents had either an indwelling catheter or open skin lesions and 2) there 
were no previously known MRSA patients. Of the study residents, 4% were bedridden. The average 
annual turnover among the long-term residents of the study wards was five, and among the short-
term residents 100. The study was carried out in each ward in one day during the week of 27 
September – 1 October 2004. 
4.4 Laboratory diagnostics of S. aureus and MRSA 
4.4.1 Sampling (studies III, and IV) 
All residents present volunteered to have their nostrils and skin lesions swabbed, and catheter urines 
cultured for studies III and IV; additionally, throats, perineal sites, and catheter exit sites were 
swabbed for study IV. 
4.4.2 Culturing (studies III, IV, and V) 
The screening swabs (Probact transport swab; Schofield St-Heywood, U.K.) were cultured onto the 
salt-containing (6.5% NaCl) enrichment trypticase soy broth (TSB) and then onto the non-selective 
SBA as a control plate for TSB in study IV, and directly onto the SBA and the ORSAB (CM1008, 
Oxoid, Hampshire, England) plates selectively supplemented with 2 mg/l of oxacillin, and 100 000 
U/l of polymyxin B (Oxoid) in study III at the KTL (Figure 2). Perineal and catheter exit site swabs, 
and catheter urines were also cultured onto the non-selective cystine lactose electrolyte-deficient 
(CLED) agar to prevent the possible overgrowth of Proteus sp. (study IV). The SBA and CLED 
agar plates, and TSB tubes were incubated aerobically at +36 (±1)°C for 24 h, and on the next day, 
were recultured from the TSB onto the SBA and the ORSAB (study IV). The SBA plates were 
incubated aerobically at +36 (±1) °C for 48 h, and the ORSAB plates for 96 h; and both were 
inspected daily (studies III and IV). The agar plates cultured on day one (SBA and CLED) were 
incubated aerobically at +36 (±1) °C for an additional 24 h (study IV). S. aureus-like colonies from 
the SBA and CLED, and blue colonies indicating oxacillin-resistant S. aureus from the ORSAB, 
were selected (one to three S. aureus colonies per specimen), subcultured onto the SBA (in the case 
of swarming Proteus sp., subcultures were also placed onto CLED in study IV), and the pure 
cultures were incubated overnight at +36 (±1)°C (studies III and IV).  
In study V, the control strains were revived from frozen stocks (-70°C), subcultured on sheep blood 
agar and incubated overnight at +37°C. The suspected MRSA strains sent by clinical laboratories 
were cultured like frozen stocks if received in rayon swabs.  
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4.4.3 Identification (studies I-V) 
S. aureus species identification was verified with Slidex agglutination test (bioMérieux, Marcy 
l´Étoile, France) in studies I, II, and V. Additional tests included nuc-PCR [Brakstad, 1992], the 
tube coagulase test, API Staph (BioMérieux, Marcy l´Étoile, France), API ID 32 Staph 
(BioMérieux, Marcy l´Étoile, France), and other microbiological fermentation tests routinely used 
in the NRL. Since the year 2000, all isolates have been tested routinely for correct species 
identification and oxacillin resistance with nuc- and mecA-PCRs, respectively (see 4.4.5). 
Microbiological fermentation tests were performed to verify S. aureus species only if the nuc-gene 
was absent. In studies III and IV, S. aureus was detected with DNAse production, the fermentation 
of mannitole and trehalose, and the Slidex agglutination test (bioMérieux, Marcy l´Étoile, France) 
(Figure 2). In study IV, the tube coagulase test was used on all S. aureus strains found, or as an 
additional test, if needed, in study III. Clinical Staphylococcus epidermidis isolates used in study V 
were identified with conventional microbiological fermentation tests. 
4.4.4 Antimicrobial susceptibility testing (studies I-V) 
Oxacillin resistance was determined with disk diffusion methods based on CLSI recommendation 
using Oxoid disks (Oxoid, Hampshire, England) for all isolates sent to the KTL for further analysis 
(studies I and II), including 164 S. aureus isolates (the 122 clinical isolates sent for mecA
confirmation, and 42 control strains) in study V, and all S. aureus isolates found (one S. aureus
colony per specimen) in studies III and IV (Figure 2). The cefoxitin disk test was also used to 
determine oxacillin resistance in studies IV and V. The MIC test for oxacillin was used for all 
isolates sent to the KTL for further analysis (studies I, II, and V), and for all S. aureus isolates 
(study III); the E-test was used according to the manufacturer’s instructions (AB Biodisk, Solna, 
Sweden) for isolates expressing disk diameters of oxacillin under 13 mm or of cefoxitin under 20 
mm (study IV). Additional resistance to erythromycin, clindamycin, gentamicin, tobramycin, 
ciprofloxacin (studies I, II, and IV), levofloxacin (study III), rifampin, trimethoprim-
sulfamethoxazole, vancomycin, teicoplanin, tetracycline, fusidic acid, linezolid (study III), 
mupirocin, and chloramphenicol (Oxoid, Hampshire, England) was tested with the disk diffusion 
method for all isolates (studies I, II, and III), or only in case of MRSA (study IV). Antimicrobial 
tests were performed in MH agar plate containing either 2% NaCl with the oxacillin disk diffusion 
test (studies I, II, and V) and E-test (studies I-V), or without the addition of salt (study V). With the 
cefoxitin disk test, the plates were incubated either with (study V) or without the addition of salt 
(studies IV and V). The plates with antimicrobial disks were incubated at +35°C, and with the E-
test, at +30°C for 24 h (studies III, IV, and V) or overnight (studies I and II). In study V, both of 
these temperatures were used to determine oxacillin and cefoxitin resistance. Resistance and 
sensitivity for antimicrobials were interpreted according to CLSI critical diameters. 
4.4.5 Verification of MRSA (studies I -V) and detection of Panton-Valentine leukocidin (PVL) 
genes (studies II and III) 
S. aureus species identification and oxacillin resistance were tested as described earlier with in-
house nuc (Brakstad et al., 1992)- and mecA (Murakami et al., 1991) -PCRs in studies I, II and V. 
DNA isolation with guanidium thiocyanate (Pitcher, 1989) preceded PCR. All biochemically 
identified S. aureus strains in study III, or S. aureus strains expressing oxacillin MIC in excess of 
two in study IV, and all 232 bacterial isolates in study V, were checked for mecA- and S. aureus- 
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specific fragments in duplicates by multiplex PCR reaction with the GenoType® MRSA test (Hain 
Lifesciences, Germany) using the reagents supplied according to the manufacturer’s instructions. 
The EVIGENETM MRSA Detection kit was used according to manufacturer’s instructions to 
identify 232 bacterial isolates in study V. PVL was determined with the GenoType® Staphylococcus
test (study III) (Hain Lifesciences, Germany) according to the manufacturers’ instructions, or with 
in-house PCR (study II) (Lina et al., 1999). 
Figure 2. Processing of screening specimens of S. aureus and MRSA in studies III and IV. CLED = cystine lactose 
electrolyte-deficient agar, SBA = sheep blood agar, TSB = trypticase soy broth, ORSAB = Oxacillin Resistance 
Screening Agar Base, MH = Müller–Hinton agar, MIC = minimum inhibitory concentration, PFGE = pulsed-field gel 
electrophoresis, MLST = multilocus sequence typing, SCCmec = staphylococcal cassette chromosome mec. 
(Subcultures in case 
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sp., study IV) 
Oxacillin disk  
diffusion and MIC 
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(study III)
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TSB + 6.5% NaCl (study IV) 
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±36°C, 
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Incubation 18 h ±36 °C 
Tube 
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4.5 Typing methods 
4.5.1 Pulsed-field gel electrophoresis (PFGE; studies II, III, IV, and V) 
All S. aureus isolates in study III, and all genetically verified MRSA isolates in studies II, IV, and 
V, were genotyped with PFGE as described elsewhere (Murchan et al., 2003). PFGE patterns were 
analyzed with BioNumerics (version 1.0 or 2.0, Applied Maths, Belgium) by using the Dice 
coefficient to analyze the similarity of the banding patterns, and with the unweighted pair group 
method using arithmetic averages (UPGMA) for cluster analysis.  
4.5.2 Multilocus sequence typing (MLST; studies II and III) 
MLST of the outbreak index strain, and one representative of each MRSA and MSSA strain with a 
similar PFGE pattern found in study III, and one representative isolate of each PFGE type in study 
II, was performed as previously described (Enright et al., 2000). Sequences of the seven house-
keeping genes were compared to data in the MLST database (www.mlst.net) and the ST was 
assigned.  
4.5.3 Staphylococcal cassette chromosome mec (SCCmec) typing (studies II and III) 
SCCmec types of each representative MRSA strain, and all MRSA findings identified with PFGE 
were determined in studies II and III, respectively. SCCmec types were determined with multiplex 
PCR as described previously (Oliveira and de Lencastre, 2002). S. aureus strains HPV 107 
(SCCmec IA), 96/32010 (SCCmec II), HSJ 216 (SCCmec type IIIA), and HDE 288 (SCCmec IV), a 
representative of the Iberian, UK-EMRSA-16, Brazilian, and Pediatric clones, respectively, served 
as SCCmec reference strains. ccrC-complex (Ito et al., 2004) and IS431-mecA (Katayama et al., 
2001) were detected with additional pairs of primes.  
4.6 Statistical methods (studies I and II) 
The Pearson correlation coefficient (and p-value) was calculated for the relationship between the 
rate of MRSA and the number of screening specimens studied to determine the screening activity of 
hospital districts (I). For categorical variables, proportions were compared by using the chi-square 
test with Yates correction or Fisher’s exact test, as appropriate (II). p-values of <0.05 were 
considered significant. 
4.7 Ethical considerations (studies I-V) 
Based on Finnish legislation, the KTL must conduct infectious disease surveillance and research in 
this research area. Similarly, Finnish clinical microbiology laboratories must report certain 
infectious disease agents and cases, including all MRSA isolations, to the NIDR. Thus, no ethics 
committee approval was required for our investigation (studies I, II, III, and V). I and my co-
workers were at liberty to collect the samples from the residents in study IV with the approval of the 
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Ministry of Social Affairs and Health as well as of the data protection authority. In addition, 
permission for sampling was requested from each individual patient. 
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5. RESULTS 
5.1 The changing epidemiology of MRSA (studies I and II) 
To analyze the epidemiology of MRSA in Finland, two studies (I and II) were performed, both of 
which dealt with MRSA notifications, whether the isolates were invasive or found from other 
sources, as well as with the distribution of MRSA based on the health care institution. A total of 
4026 MRSA notifications were reported to the NIDR (120-1458 per year) from 1997 to 2004. The 
annual incidence of MRSA notifications was 2.3 cases per 100 000 population in 1997, and 27.9 in 
2004 (Figure 3). Of the 4026 MRSA notifications, 71 were obtained from blood and 4 from CSF; 
30 of the blood isolates and 3 of the CSF isolates were from the year 2004. The proportion of 
MRSA among blood isolates of S. aureus rose from below 1% to 2.8% in 2004. From 1997 to 2004, 
the numbers of MRSA notifications were strikingly high in three hospital districts (HDs) and in six 
others experienced an increasing trend (Figure 4). In two HDs, the average annual incidence rate 
was more than 15 cases per 100 000 population and in six HDs, it varied between 10 and 15 cases 
(Figure 5). Of the HDs with a rate of ten or more cases per 100 000, two were located in Central 
Finland, two in Eastern Finland, and three in Northern Finland. The average annual incidence rates 
of MRSA notifications were lowest in the western parts of Finland.  
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Figure 3. Annual incidence of MRSA notifications and the proportion of MRSA among S. aureus blood isolates, 
Finland, 1997-2006.  Source: NIDR 
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Figure 4. Annual number of MRSA notifications in Finnish hospital districts, 1997-2006. Source: NIDR. 
Figure 5. The average annual incidence rate of MRSA notifications per 100 000 population in Finnish hospital districts, 
1997-2004. 
The age and gender of MRSA-positive persons registered with the NIDR, and the antimicrobial 
resistance of strains sent to the NRL from 1997 to 2002 were analyzed. The median age of 1718 
persons with MRSA was 63 years (range: 0-101) and 49% were male. The proportion of patients 
aged 65 or more years doubled from 31% to 63% in hospital districts outside the Helsinki 
metropolitan area. Antimicrobial resistance was studied from a total of 1702 MRSA isolates sent to 
the NRL. From 1997 to 2002, NMDR isolates of MRSA increased from 41% (56/137) to 67% 
(387/579), respectively. Of those NMDR isolates, 14% (8/56) and 29% (112/387) were oxacillin-
resistant only, respectively. In general, NMDR MRSA was more common outside the Helsinki 
metropolitan area. Very low-level oxacillin resistance (MIC 2 μg/ml) was detected in 2% 
(36/1702) of the MRSA strains. Half of these (18/36) included NMDR, and 10 in 18 of these were 
resistant only to beta-lactam antibiotics.  
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Based on the questionnaire, the median number of screening specimens studied was 404 per 100000 
population in 2001 (range by hospital district, 0-2768; Figure 6).  At the same time, the median rate 
of MRSA was 11 per 100000 population (range by hospital district, 0-48). The high rate of MRSA 
failed to correlate with the high number of screening specimens studied (Pearson correlation 
coefficient 0.18; p>0.05). According to the same questionnaire, the CLSI guidelines were variably 
followed in Finnish microbiological laboratories in 2001. The oxacillin disk diffusion test was 
carried out in 74% (17/23) of the laboratories, while 35% (8/23) of the laboratories used an 
incubation period of only 18 h (instead of 24 h) and a temperature of 30°C (instead of 35°C). The 
amount of salt added to the agar base varied from 0% to 5%, and only 30% (7/23) of the 
laboratories followed CLSI recommendations, which recommend a 2% NaCl concentration. Ninety-
one percent (21/23) of the laboratories reported using the oxacillin-MIC E-test and a specific 
MRSA screening agar media routinely; 60% of them used ORSAB. A latex agglutination test for 
the detection of the PBP2a protein was routinely used in 50% of the laboratories. A PCR-based test 
for mecA was used in only one laboratory.  
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Figure 6. MRSA isolates and the number of screening specimens studied by hospital district in 2001. 
Questionnaires about the situation in long-term facilities in 2001 (study I), and about the 
background information of MRSA-positive persons in 2001-2003 (study II) were sent to the 
infection control nurses; response rates were 95% (20/21) and 97% (1707/1768), respectively.  
MRSA was found in 14 of the 20 HDs in LTFs in 2001. The total number of LTFs involved with 
MRSA was 58 (39 health care center wards, 11 NHs, 1 center for the mentally disabled, 1 
rehabilitation center, and 6 others). Eighty percent (152/189) of the findings were from patients and 
20% (37/189) from staff members. The findings comprised more than half of the notifications to the 
NIDR in 2001 (189/340).  
From 2001 to 2003, a total of 1598 (94%) MRSA strains were found among patients and 109 (6%) 
among staff members. Among the patients, 796 (50%) of the specimens were taken on a clinical 
basis, 690 (43%) on a screening basis after exposure to MRSA, 65 (3%) on a screening basis 
because of hospital contact abroad, and 72 (4%) for other reasons. The corresponding figures 
among the staff members were 12 (11%), 73 (67%), 19 (17%), and 5 (5%), respectively. Screening 
specimens obtained from patients after exposure to MRSA increased from 36% (96/265) in 2001 to 
42
45% (364/816) in 2003, and those obtained from staff members in epidemic situations increased 
from 46% (12/26) in 2001 to 82% (36/44) in 2002, but decreased to 64% (25/39) in 2003. A rising 
trend in the proportion of screening specimens was observed in seven HDs, including two HDs with 
a strikingly high rate of MRSA notifications. In nine HDs, no such trend occurred and in four HDs, 
the proportion decreased (Table 5). 
 Table 5. The numbers and proportions of clinical and screening findings of MRSA by hospital districts (HD) during the 
study period 2001-2003 in Finland
no. of clinical finding no. of screening findings clinical-% screening-%   
HD 2001 2002 2003 2001 2002 2003 2001 2002 2003 2001 2002 2003 
HUS 31 44 110 15 35 116 67 56 49 33 44 51 
VAR 4 3 8 10 5 27 29 37 23 71 63 77 
SAT 1 5 7 3 6 9 25 45 44 75 55 56 
KHÄ 3 4 2 1 10 0 75 29 100 25 71 0 
PIR 36 80 113 5 46 124 88 63 48 12 37 52 
PHÄ 2 7 17 0 2 14 100 78 55 0 22 45 
KYM 0 1 1 0 4 8 0 20 11 0 80 89 
EKA 3 2 9 2 0 70 60 100 11 40 0 89 
ESA 17 15 13 46 20 3 27 43 81 73 57 19 
ISA 8 8 8 6 2 0 57 80 100 43 20 0 
PKA 7 10 12 5 9 13 58 53 48 42 47 52 
PSA 13 13 14 6 10 10 68 57 58 32 43 42 
KSU 9 16 13 21 12 1 30 57 93 70 43 7 
EPO 3 5 2 2 0 0 60 100 100 40 0 0 
VAA 0 3 3 0 0 3 0 100 50 0 0 50 
KPO 1 3 7 0 1 2 100 75 88 0 25 12 
PP0 14 22 22 5 129 32 67 14 41 33 86 59 
KAI 9 2 6 10 1 14 47 67 30 53 33 70 
LPO 1 3 3 5 1 2 17 75 60 83 25 40 
LAP 4 6 4 4 8 20 50 43 17 50 57 83 
5.2 Nationwide trends in the molecular epidemiology of MRSA (study II)  
To assess recent trends in the molecular epidemiology of Finnish MRSA strains, a total of 4091 
MRSA isolates sent to the NRL from 1997 to 2004 were analyzed. With PFGE, 253 different strain 
types of which 38 were outbreak/epidemic and 215 sporadic strains were identified. From 1997 to 
2004, 24 new outbreak/epidemic strain types appeared (Table 6). The proportion of sporadic strains 
varied between 3% and 13% during the study period, but overall showed a decreasing trend. 
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At the beginning of the study period (1997-2001), the distribution of different strain types was more 
diverse, but since 2002, five strain types were the most predominant (FIN-16 (ST125:IA), FIN-4 
(ST375:IV), FIN-21 (ST228:I), FIN-7 (ST8:IV), and FIN-10 (ST45:IV and V) (Figure 7). In 2004, 
more than half of the strains (53%) found were comprised of FIN-16 and FIN-21 (ST228:I) strains. 
FIN-16 increased from <1% in 1997 to 25% in 2004 and was found in 15 HDs (Table 6), but the 
majority (554/742; 75%) of all FIN-16 strains was found in one HD in Central Finland. The 
proportion of the FIN-21 strain increased from 6% in 2002 to 28% in 2004, and only a minority of 
the strains were found outside the Helsinki metropolitan area (9/581; 2%). The most common 
MRSA isolates found from blood and from CSF in 2004 were FIN-16 (12/34), FIN-21 (9/34), and 
FIN-4 (4/34); no significant associations were found either between the type of specimen (blood 
and CSF vs. other) and these strains in 2004 or during the entire study period. 
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Figure 7. The distribution of MRSA strains, Finland, 1997-2004. 
FIN-4 (including also FIN-4a and FIN-4b strain types; ST375:IV) was the second most often 
isolated strain, and was found in every HD (range annually 7-17 HD) in Finland during the study 
period (Table 6).  FIN-7 (ST8:IV) and FIN-10 (ST45:IV or V) strains have also been found in the 
majority of HDs, but mostly in three (341/495; 69%) and six (336/448; 75%) HDs, respectively (the 
annual range in the number of hospital districts: 3-13 and 3-15, respectively).  
Combining the additional background information on MRSA-positive persons (see also results in 
5.1), with the PFGE results showed that FIN-16 strains were more likely to occur in clinical 
specimens than in those obtained on a screening or other basis (199 [25%] of 805 vs. 160 [18%] of 
902; p < 0.05) (Table 7). On the contrary, FIN-21 strain was tended to be found more often from 
screening and other specimens than from those taken on clinical basis (58 [7%] of 805 vs. 87 [10%] 
of 902; p=0.086). FIN-4 was more likely to occur among isolates obtained from patients and staff 
members on a clinical basis than in screening (167 [21%] of 805 vs. 81 [9%] of 902; p<0.05). FIN-7 
(ST8:IV) and FIN-10 (ST45:IV) were more likely to occur in screening specimens of patients and 
staff members than in their clinical specimens (70 [9%] of 805 vs. 194 [22%] of 902; p<0.05, and 
89 [11%] of 805 vs. 149 [17%] of 902 ; p<0.05).  
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Of the representative strains, FIN-11 (ST80:IV) and FIN-25 (ST:IV) tested PVL positive (Table 6). 
In addition, some strains of FIN-5 (ST-30:IV) and FIN-19 (ST1-IV) possessed lukS-PV - lukF-PV 
genes that encode for PVL (Table 6). 
Table 7. Background information on patient and staff members who tested positive for the ten most common epidemic 
MRSA strains, 2001-2003.
aOf the FIN-2 strain, the FIN-2e subtype caused the epidemic. 
bThe total number of strains (1721) exeeds the number of MRSA-positive persons (1707) by 14 because in some cases more than one 
reason for sampling was chosen in the questionnaire. 
5.3 Methicillin-sensitive S. aureus (MSSA) and MRSA in Finnish long-term facilities (studies 
III and IV) 
5.3.1 Prevalence of MSSA and MRSA among long-term facility residents 
At the time of the point-prevalence survey carried out in Northern Finland (study III), a total of 90 
specimens, 76 from the nostrils, 10 from skin lesions, and 4 from catheter urine, were obtained from 
76 of 80 in-patient volunteers (Table 8). Of the 90 specimens, 30 (33%) tested positive for S. aureus 
and 5 (17%) tested positive for MRSA. Of the 76 patients, 24 (32%) were S. aureus carriers and 5 
(20%) tested positive for MRSA; the prevalence of MRSA was 7%. Two of the five MRSA isolates 
came from patients who tested positive during the outbreak in 2003 (one from a NH, and another 
from a HCW), one of the patients tested positive for MRSA for the first time nine days before the 
point-prevalence survey in February 2004 (from a NH), and two of the patients were new carriers 
(both from a NH). Of the 13 patients who previously tested positive for MRSA during the outbreak 
in 2003, five died, one was discharged, and five were culture-negative for MRSA at the time of the 
point-prevalence survey.  
Number of patients (1598) Number of staff members (109) 
MRSA 
strain 
Sequence 
type (ST) 
and 
SCCmec
type 
Clinical 
speci-
men 
Screening 
specimen; 
exposure 
to MRSA 
Screening 
specimen; 
hospital 
contact 
abroad 
Other 
reason 
for 
taking 
the 
sample 
Clini-
cal 
speci-
mens 
Scree-
ning 
speci-
men; 
epidemic 
situation 
Scree-
ning 
speci-
men; 
hospital 
contact 
abroad 
Other 
reason 
for 
taking 
the 
sample 
Total 
no. of 
isolates 
FIN-16 ST125:IA 197 131 5 18 2 3 1 2 359 
FIN-7  ST8:IV 70 159 1 6 - 28 - - 264 
FIN-4 ST375:IV 163 56 5 12 4 8 - - 248 
FIN-10 ST45:IV, V 87 129 2 6 2 12 - - 238 
FIN-21  ST228:I 58 82 1 3 - 1 - - 145 
FIN-3 ST5:II 22 30 8 7 - 4 - - 71 
FIN-15 ST8:IV 34 19 - 5 - 9 - 1 68 
FIN-12 ST22:IV 19 12 8 4 - 1 14 - 58 
FIN-6 ST36:II 5 1 5 - - 1 1 - 13 
aFIN-2 ST241:IIIB 7 - 2 - - - - - 9 
Other 
strains  79 49 8 2 3 5 2 2 150 
Sporadic  52 22 19 2 1 1 1 - 98 
Total  793 690 64 65 12 73 19 5 b1721 
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In study IV, different body sites were evaluated for their ability to detect S. aureus carriage. Of the 
217 residents present at the selected ward in the largest NH in the Helsinki metropolitan area, 4 
completely refused sampling, and of the remaining 213, 3 (1.4%) refused nostril swabbing, 15 
(7.0%) throat swabbing, and 8 (3.8%) perineal swabbing. A total of 663 specimens (median: 3; 
range: 1-7) were obtained from 213 patients: 165 specimens (25%) from 94 patients (44%) tested 
positive for S. aureus, and 3 specimens (0.4%) from 2 (0.9%) patients in the same ward tested 
positive for MRSA (Table 8). The highest proportion of S. aureus growth was obtained from the 
catheter exit sites (56%, 5/9), and lowest from the perineum (13%, 27/207) and catheter urine (19%, 
3/16). Of the 165 S. aureus isolates, 32 (19%) were obtained only from sites other than the nostrils 
from a total of 25 patients: 11 specimens came from the throat, 7 from the perineum (6 MSSA and 1 
MRSA), 2 from skin lesions, 1 from the catheter exit site, 6 from a combination of the throat and 
perineum of three patients, 2 from a combination of the perineum and a skin lesion of one patient, 
and 3 from a combination of the throat, perineum, and a skin lesion of one patient.  
Table 8. The prevalence of S. aureus (MSSA and MRSA) isolates among 90 and 663 specimens from 76 and 213 
residents in a Finnish nursing home from studies III and IV, respectively. 
Screening 
site 
Total no. of 
specimens,  
studies III / 
IV 
No. of specimens, 
positive for S. 
aureus (%), 
studies III / IV 
Growth of S. aureus
only with TSB 
enrichment (%), 
study III   
No. of 
specimens, 
positive for 
MRSA, 
studies III / IV 
Growth of 
MRSA in 
ORSAB, 
studies III / 
IV 
Nostrils 76 / 210 24 (32) / 69 (33) 10 (14) 4 / 1 2  / 1  
Throat ND / 198 ND / 53 (27) 7 (13) ND / - ND / - 
Perineum ND / 207 ND / 27 (13) 13 (48) ND / 1  ND / -  
Skin lesion 10 / 23a) 5 (50) / 8b) (35) 3 (38) 1 / - 1  / - 
Catheter 
exit site ND / 9 ND / 5 (56) - ND / 1  ND / 1  
Catheter 
urine 4 / 16 1 (25) / 3 (19) - - / - -/- 
Total 90 / 663 30 (33) / 165 (25) 33 (20) 5 / 3 3  / 2  
a)Taken from 16 residents. 
b) Found in seven residents. 
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Table 9. The genotypes and antimicrobial resistance of MRSA and MSSA strains determined with PFGE in studies III 
and IV. A minus (-) means not found. 
No. of isolates No. of patients PFGE 
strain name MRSA, 
studies III / IV 
MSSA, 
study III 
MRSA, 
studies III / IV 
MSSA 
study III 
Antimicrobial 
resistance of  
MRSA / MSSA
FIN-22 2 / - 3 2 / - 3 beta-lactams / none 
FIN-21 - / 2 - - / 1 - 
beta-lactams 
gentamycin tobramycin 
erytromycin 
clindamycin 
ciprofloxacin  
FIN-7 3 / 1 3 3 / 1 3 beta-lactams / none 
FIN-14 - / - 5 - / - 3 - / none 
FIN-10 - / - 6 - / - 6 - / none 
FIN-16 - / - 1 - / - 1 - / none 
Sporadic - / - 7a - / - 6 - / noneb
Totalc 5 / 3 25 5 / 2 22  
a One patient in study III had two identical sporadic MSSA strains in different sites. 
b One of the seven sporadic strains was resistant to chloramphenicol. 
c The total number of patients (27) exceeds the real number (24) by three because of duplicate genotype findings in study III. 
5.3.2 Detection of MSSA and MRSA among long-term facility specimens 
Screening specimens of S. aureus and MRSA obtained from two Finnish LTFs were investigated at 
the NRL. All five MRSA isolates found in study III were resistant only to oxacillin (Table 9), 
expressing an oxacillin MIC of 2-32 mg/l. Two isolates found in new carriers expressed oxacillin 
MICs of 2 and 4-6 mg/l, respectively, failed to grow on the ORSAB with 2 mg/l of oxacillin. All 25 
MSSA strains were sensitive to all antimicrobials tested, except one strain, which was resistant to 
chloramphenicol (Table 9). 
In study IV, the necessity of performing broth enrichment to increase sensitivity, and the usability 
of ORSAB, which is widely used in routine diagnostics in Finland were assessed. TSB enrichment 
detected an additional 33 (5%) S. aureus isolates (32 MSSA, and 1 MRSA) in a total of 28 patients 
compared to both selective and non-selective agar plating, which resulted in finding 8 (4%) 
additional S. aureus-positive patients (Table 8). Four S. aureus isolates (0.6%), two from the 
nostrils and two from the throat, were found only in SBA used as a control plate for TSB in a 
primary culture. Four S. aureus isolates were isolated only in CLED, of which two were from 
primary cultures of the perineum, and two from subcultures of the nostrils because of swarming 
Proteus sp. Within 96 h, 187 of the 663 (28%) specimens grew in ORSAB, 2 (1%) of which were 
MRSA. Of the 187 cultures, half (94/187) were from the perineum, and 46 (25%) developed blue 
colonies within 24 h. The two multi-drug-resistant MRSA strains isolated from the nostrils and a 
catheter exit site in the same resident grew in ORSAB within 24 h, but the non-multi-drug-resistant 
MRSA strain, isolated from the perineum and expressing an MIC of 6 mg/l, did not.  
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5.3.3 Molecular epidemiology of MSSA and MRSA in long-term facilities 
 
In study III, a total of 30 S. aureus isolates obtained from 24 patients were analyzed with PFGE, 
and 11 different PFGE profiles were detected (Table 9). Of five MRSA isolates, two isolates 
showed a FIN-22 PFGE profile and three isolates showed a genotype of another Finnish epidemic, 
the FIN-7 PFGE profile MRSA strain. MLST characterized two representative strains of FIN-22 
and FIN-7 (one MRSA and one MSSA) as ST-27 and ST-8, respectively. All five MRSA strains 
possessed the F-locus typical for SCCmec type III (414 bp) detected by multiplex-PCR. The strains 
tested negative, however, for recombinase genes ccrA and ccrB, but possessed ccrC detected with 
specific primers; thus the strains belonged to SCCmec type V (Figure 8). None of the 30 S. aureus 
(MRSA and MSSA) strains tested positive for the PVL gene.  
 
Three of the MSSA strains were genotypically related to the FIN-22 strain, and three to the FIN-7 
MRSA strain (Table 9). Twelve MSSA strains from ten different patients were related to three other 
Finnish epidemic MRSA strains, and seven strains from six different patients were considered 
sporadic. One patient was colonized with two genotypically different MSSA strains: FIN-7 was 
found in his nostril and FIN-10 in his skin lesion. Two patients were widely colonized with the 
same MSSA strain: one (FIN-14) was found in a nostril, urine, and skin lesion, and another 
(sporadic) strain in a nostril and skin lesion. The two patients colonized with both MRSA and 
MSSA possessed strains of different genotypes. One had the FIN-22 MRSA strain in his skin lesion 
located on his back, and the FIN-10 MSSA was found in his nostril; the other patient had both FIN-
7 MRSA and FIN-10 MSSA in her nostril. 
 
In study IV, two MRSA strain types were identified with PFGE typing: non-multidrug-resistant 
strain FIN-7 in one patient, and a multidrug-resistant strain FIN-21 in another patient (Table 9).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Patient MRSA strains 1-5 (lanes 3-7), positive control for SCCmec type V (FIN-10; lane 1), negative control 
for SCCmec type V (Pediatric; lane 2), and the DNA-size molecular marker pUC (in upper gel; lane M), and XVII (in 
lower gel; lane M). 
  M    1     2      3      4     5      6     7    M 
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5.4 Phenotypic detection of MRSA (study V) 
With cefoxitin disk diffusion using interpretive zone diameters of R  19 mm, 100% sensitivity and 
100% specificity at +35°C with or without the addition of salt according to mecA status was 
obtained (Table 1). When MH plates were incubated at +30°C, the specificity remained at 100%, 
but sensitivity decreased to 94.7% and 97.3% with or without the addition of salt, respectively. 
With the oxacillin disk diffusion test, a sensitivity of 100%, but 99.3% when incubating at +30°C 
without the salt addition was obtained. Specificity was 35.7% and 50% at +35°C with or without 
the salt addition, respectively, and 21.4% and 42.9% at +30°C with or without the salt addition, 
respectively. With the oxacillin E-test, a sensitivity of 94% at both +35°C and +30°C without the 
salt addition and 99.3% at +35°C and 98.7% at +30°C, both with the salt addition was obtained. 
Specificity was 57.1% at both +35°C and +30°C with the salt addition, and 92.8% at +35°C and 
78.6% at +30°C, both without the salt addition. 
Table 10. Comparison of resistance determination performed by oxacillin and cefoxitin disk diffusion methods and E-
test MIC-method in mecA-positive and -negative S. aureus strains.  
Number of strains 
Incubated with MH 
in +35°C 
Incubated in 
MH+NaCl +35°C 
Incubated with MH 
in +30°C 
Incubated in 
MH+NaCl +30°C 
Oxacillin 1 μg 
12 mm 13 mm 12 mm 13 mm 12 mm 13 mm 12 mm 13 mm 
Positive 
(150) 150 0 150 0 149 1 150 0 
Negative 
(14) 7 7 9 5 8 6 11 3 
Cefoxitin 30 μg 
19 mm  20 mm 19 mm  20 mm 19 mm  20 mm 19 mm  20 mm 
Positive 
(150) 150 0 150 0 146 4 142 8 
Negative 
(14) 0 14 0 14 0 14 0 14 
Oxacillin-MIC 
3 2 3 2 3 2 3 2 
Positive 
(150) 141 9 149 1 141 9 148 2 
Negative 
(14) 1 13 6 8 3 11 6 8 
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5.5 Genotypic verification of MRSA (study V) 
All 164 S. aureus isolates tested positive for the nuc gene, and 150 of those also tested positive for 
the mecA gene with the used in-house PCR tests. With Geno Type® MRSA, both the detection of 
mecA and amplicons specific to the S. aureus species corresponded perfectly with the results 
obtained with in-house PCR. Geno Type® MRSA also correctly detected all 42 Staphylococcus 
epidermidis strains, of which 38 possessed the mecA gene. The results for both Enterococcus 
isolates and all ATCC reference strains were in concordance with those of in-house PCR. The 
EVIGENE™ MRSA Detection test correctly identified all 164 S. aureus strains that tested positive 
for nuc, and 150 strains that tested positive for mecA. With three S. aureus strains, the nuc gene was 
slightly below the cut-off level, but the strains were visually interpreted as positive. 
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6. DISCUSSION 
6.1 The changing epidemiology and molecular epidemiology of MRSA in Finland  
MRSA has become a persistent problem worldwide. Rising MRSA rates have also been observed in 
Finland, especially among the elderly. The present study shows a consistent year-to-year rise in the 
annual number of MRSA isolates in Finland from 1997 to 2004. Before the year 2003, the rise 
occurred mostly outside the Helsinki metropolitan area where NMDR MRSA also was more 
common. In the Helsinki metropolitan area, MDR MRSA dominated the entire study period. MDR 
MRSA is typically found more often in acute care hospitals, and NMDR outside hospitals 
(Salmenlinna et al., 2002). The rise in the incidence of MRSA, compared to that of the entire 
country, remained one of the lowest in Southwestern Finland. The screening activity was, however, 
the highest in Southwestern Finland during 2001. In general, the screening activity failed to 
correlate with the rate of MRSA. HDs with a low rate of MRSA were usually characterized by high 
screening activity and vice versa. This could be due to a different screening activity policy between 
HDs or to an ongoing outbreak in that year. 
In 2001, the number of MRSA cases rose among elderly persons outside the Helsinki metropolitan 
area, and 58% of all persons with MRSA were found in nursing homes. The survey on the MRSA 
situation, however, covered only one year, and the clinical data and risk factors for MRSA 
acquisition in Finnish long-term facilities were unavailable. It can only be assumed that most of the 
MRSA findings in Finnish long-term care facilities were found from screening specimens, since it 
is generally known that clinical infections are rarer in long-term care than in acute-care hospitals 
(Bradley, 1999).  
The most recent rise was related to the spread of two internationally recognized MDR MRSA 
strains, FIN-16 (ST125:IA) and FIN-21 (ST228:I), which also caused a striking increase in blood 
and CSF findings. A similar rise in ST125:IV clones in Spanish hospitals was also reported (Perez-
Roth et al., 2004). A single ST125 strain has also been found in Norway (http://www.mlst.net), but 
the SCCmec type was not reported. Most of the FIN-16 strains were found from clinical specimens, 
and FIN-16 was the most common strain isolated from invasive specimens in 2004, indicating that 
it may be virulent and have epidemic potential. Since FIN-16 dominated one HD for four years, it 
can be considered as an endemic strain in that area, especially in long-term facilities. Thus, it can 
equally be assumed that its capacity to cause clinical infections occurs simply because the FIN-16 
strain has reached a sufficiently high level among the population, especially among the oldest and 
diseased patients who are transferred between LTFs and acute-care hospitals. The FIN-21 strain was 
found in Finland for the first time in September 2002 (Kanerva et al., 2007), and only few of these 
strains were found outside the Helsinki metropolitan area. In the NH in the Helsinki metropolitan 
area, two of the three MRSA strains found there were FIN-21, and only one patient was colonized 
with this strain. This was quite an unexpected result, since this strain has recently caused many 
epidemics in secondary- and tertiary-care hospitals in the Helsinki metropolitan area. The strain had 
a PFGE pattern similar to the Italian clone (Mato et al., 2004), and expressed also MLST allelic 
profile ST 228, and carried SCCmec type I. Isolates of MRSA with the same ST228 were reported 
as a “South Germany” epidemic clone (Cookson et al., 2007; Murchan et al., 2003; Petersdorf et al., 
2006). The strain was isolated more often from screening specimens than from those taken on a 
clinical basis, contrary to the tendency with FIN-16. This may be due to differences in MRSA 
screening activity between the HDs, or to the subsequent appearance of the strain in Finland. The 
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outbreaks differed, however, in their epidemiology: FIN-16 prevailed in LTF and FIN-21 in acute-
care hospitals. 
Almost 60% of the MRSA strain types carried SCCmec IV or V, which are often seen in CA-
MRSA (Ito et al., 2004; Zetola et al., 2005). However, only four strain types harbored PVL 
encoding genes, another marker that has been used to identify of CA-MRSA (Miller et al., 2007; 
Seybold et al., 2006) and has been linked to the development of furuncles, abscesses, and severe 
necrotic infections (Lina et al., 1999). The majority of all Finnish MRSA strains previously 
associated with community acquisition possessed type IV SCCmec, but only a minority (12%) of 
them were PVL positive (Karden-Lilja et al., 2007). As reported elsewhere, most of the PVL- 
positive strains, however, were ST80 (Faria et al., 2005; Witte et al., 2005). FIN-4 (ST375), the 
most commonly found strain possessing SCCmec type IV, was associated with clinical infections 
among patients more often than the two other commonly found SCCmec IV-expressed strains, FIN-
7 (ST8) and FIN-10 (ST45). A previous Finnish study covering the years 1997-1999 showed that 
the FIN-4 strain was one of the three epidemic strains found most often in patients with no health 
care setting contact, thus suggesting that these MRSA strains were community acquired 
(Salmenlinna et al., 2002). Unfortunately, no health care records were available in this present 
study, so it cannot be assessed whether acquisition of these three strains is still associated with the 
community. Interestingly, FIN-4 strains, which were not considered internationally spread epidemic 
strains, were found in five patients with hospital contact abroad. Although those strains may also be 
endemic elsewhere in the world, these patients may have been infected with MRSA in Finland 
before or after their hospital contact abroad. However, ST375 has recently been shown to spread in 
Denmark, where it has been identified as CA-MRSA (Faria et al., 2005).  
The FIN-7 strain was the fourth most common strain type found in our study. It belongs to ST8 
clones, which occur worldwide, and have been reported to express four different SCCmec types (I-
IV), mainly type IV (Aires de Sousa and de Lencastre, 2003; Chung et al., 2004; Enright et al., 
2002). ST8:IV strains have been reportedly associated with community acquisition (Carleton et al., 
2004), although they have recently been reported to cause infections in health care facilities 
(Seybold et al., 2006). FIN-7 was also found in residents who tested positive for MRSA in both NH 
studies, although these strains expressed type V SCCmec.  
The fifth most commonly found strain type was FIN-10, which belongs to the ST45 clones. ST45 
clones have been reported to spread widely both as MSSA and as MRSA in Scandinavia, Western 
Europe, and the USA (Enright et al., 2002). Moreover, ST45 clones were also found in a hospital in 
Miami, Florida, where they were considered community-acquired (Chung et al., 2004). Wannet and 
colleagues have reported that MRSA ST45 was recognized for the first time in the Netherlands in 
2000 and reached epidemic proportions in 2002 (Wannet et al., 2004). In contrast to other studies, 
they described MRSA ST45 as having low-level resistance (4 to 32 mg/liter; median: 8 mg/liter) to 
oxacillin. The Finnish main representative strains of ST45:IV and ST8:IV (FIN-10 and FIN-7, 
respectively) were resistant to oxacillin alone and expressed a heterogeneously resistant phenotype.  
The annual proportion of sporadic strains has decreased during the study period, although their total 
number has remained almost unchanged or has slightly increased, indicating that new strain types 
still emerge. As the routine typing repertoire and the MRSA PFGE database have increased in 
volume, it is likely that common ancestors can more easily be found for a greater number of 
“sporadic” strains. On the other hand, sporadic strains have been speculated to possess a worse 
environmental survival capacity than epidemic strains (Wagenvoort et al., 2000). Sporadic strains 
are thought to be more often community acquired, whereas hospital-acquired MRSA strains are 
more often endemic (Blanc et al., 2002; Petersdorf et al., 2006). Most of Finnish sporadic strains 
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were found in the clinical specimens, but one fifth of them originated from persons who had had 
hospital contact abroad. Blanc and colleagues have reported that at least one-third of the sporadic 
strains found in Switzerland resulted from the ongoing introduction of new strains from abroad 
(Blanc et al., 2002). They have also shown that most Swiss sporadic isolates were related to other 
European epidemic MRSA clones (Blanc et al., 2000). One cannot be sure of the origin of Finnish 
sporadic strains because the routine molecular typing scheme is based primarily on the highly 
discriminatory PFGE, which allows the detection of genomic microevolution, unlike MLST. 
Finnish sporadic strains may have descended from a few ancestors, a fact which could have been 
detected with MLST and eBURST as well as with spa typing.  
Because the NIDR notifications include only the source of the specimen, rather than whether the 
specimen is taken on a screening or clinical basis or whether further data on clinical 
specimens/infections are available, the survey was performed in 2001-2003 in order to make this 
crucial distinction. The proportion of screening specimens among the patients and staff members 
increased during the study period, and almost half of the MRSA findings were found in patients’ 
screening specimens. This active screening policy may partly be related to the rise in the number of 
MRSA cases that was detected, but likely had no influence on the worrying trend in blood and CSF 
findings. Thus, it is believed that the spread of MRSA has increased, as indicated by each new 
MRSA case. It is also very likely that there are some differences not only in resources for, but also 
in experiences with MRSA control in long-term care as well as in health care settings. 
6.2 S. aureus in Finnish long-term facilities 
6.2.1 MSSA and MRSA colonization among Finnish long-term facility residents 
In the Northern Finnish LTFs, the point-prevalence survey showed that the prevalence of MRSA 
was 7%, and that of MSSA, 32%. In the second largest Finnish NH in the Helsinki metropolitan 
area, MSSA colonization was 44%, but the prevalence of MRSA was low: 0.9%. The MRSA 
colonization rates differed between these facilities due to an outbreak of MRSA in the Northern 
LTF. Differences in colonization rates may also depend on the presence of invasive devices and 
skin lesions, the type and severity of the underlying conditions of residents, and infection control 
practices at the LTF (Bradley, 1999). One limitation of the study III was that only nostrils of all the 
participating patients were screened, although skin lesions were also screened if present. Studies 
have reported that a combination of three body sites (nose, throat, and wounds/skin lesions) are 
necessary to detect all MRSA (Muto et al., 2003; O'Sullivan and Keane, 2000b). However, with the 
methods that were used, it was possible to detect two new carriers who tested MRSA-negative nine 
days before being screened by local authorities.  
In study IV, different body sites for the ability to detect S. aureus carriage were evaluated. The 
highest rates of S. aureus colonization in catheter exit sites were detected, although only a few 
residents had them. These results are consistent with those of earlier LTF studies (Bradley, 1999). 
The omission of sampling sites other than the nostrils would have missed 12% (24 MSSA and one 
MRSA case) of the S. aureus-positive residents. Perirectal- perianal cultures have been shown to 
detect MRSA with high sensitivity in certain patient populations (Muto et al., 2003), although the 
cost effectiveness has shown little support for perianal screening in some cases (Papia et al., 1999).
On the other hand, Coello and colleagues reported that in non-infected asymptomatic carriers, the 
perineum swab alone or in combination with a nose swab was more sensitive than the throat swab 
alone or in combination with a nose swab (Coello et al., 1994). Two recent studies, however, 
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concluded that samples taken from the throat should be included in screening patients for MRSA 
(Meurman et al., 2005; Ringberg et al., 2006). Nevertheless, collecting throat swabs from elderly 
persons suffering from dementia can be troublesome, and in the present study, the refusal rate with 
throat swabbing was the highest. Thus, swabbing the perineum while being washed could be a more 
comfortable way of sampling. The limitation in both of these studies was that only one screening 
round was carried out. The duration of MRSA carriage has been reported to last three to four 
months in LTFs (Bradley et al., 1991; Muder et al., 1991), but the status may have changed during 
the study, thus suggesting intermittent carriage (O'Sullivan and Keane, 2000b). Adequate 
differentiation between persistent and intermittent carriers would be relevant for epidemiological 
studies because of the increased risk for S. aureus infections with persistent carriers (Bruun, 1970). 
In addition, studies have shown bacterial genotypic variability to be lower for persistent carriers 
than for intermittent carriers, thus indicating that the underlying mechanisms that determine 
persistent and intermittent carriage differ (van Belkum et al., 1997). 
6.2.2 The molecular epidemiology of MRSA and MSSA strains 
Study III described the original MRSA outbreak consisting of isolates possessing a nationally new 
PFGE profile and internationally rare MLST type. In addition, three MRSA strains related to the 
FIN-7 profile were also detected. The outbreak of FIN-22 PFGE and ST-27 MLST types has been 
identified from only one Finnish patient outside this remote Finnish municipality, and the 
international MLST website showed that the MLST profile of that outbreak strain matched only 
three MSSA strains isolated from healthy carriers in England. However, no connections are known 
to have existed between these single individuals and those 13 residents in the LTF in Northern 
Finland. Among the 25 MSSA and 5 MRSA strains, 11 different PFGE patterns obtained from 24 
different persons indicate the wide dissemination of different S. aureus genotypes in the small LTF 
population studied. In addition, two of the patients were colonized with S. aureus strains possessing 
two different MSSA and MRSA genotypes, and one of the patients was colonized with two 
different MSSA strains. According to Cespedes and colleagues, approximately 7% of S. aureus-
colonized persons could be expected to carry more than one strain in their nostrils (Cespedes et al., 
2005). A limitation of the present study was that only one MSSA strain per sample was studied, and 
therefore genotypically different MSSA strains from the same patient may have been missed. In 
addition, the nursing staff was not screened, so it cannot be known whether they carried the same 
genotype of S. aureus. However, six of the MSSA strains from six different patients were related to 
MRSA genotypes found in this study, and altogether 18 of 25 (72%) MSSA strains from 15 patients 
were related to Finnish epidemic MRSA strains, and especially to the FIN-10 and FIN-14 strains. 
The present data from a Finnish study revealed that despite the rather wide genomic diversity, most 
clinical MSSA isolates share identical genotypes with the non-multiresistant Finnish epidemic 
MRSA strains, including the FIN-7 strain (Ibrahem et al., 2005). 
All the MRSA strains found in this survey shared identical SCCmec V, indicating that the same 
mobile genetic element has been integrated into the S. aureus chromosome of the strains in the 
patients. Among the epidemic strains in Finland, two other strain types, FIN-10d and FIN-17, also 
share SCCmec type V. FIN-10d has spread in Northern Finland and is resistant mainly to beta-
lactams. Recently, at least one more strain type possessing SCCmec V has been identified in 
Finland (unpublished data). SCCmec V is reportedly to associated with community acquisition and 
distributed among coagulase-negative staphylococcal species, especially S. haemolyticus (Ito et al., 
2004). Some have speculated that the mec gene complex and ccr gene complex of SCCmec go over 
complex rearrangement and recombination processes in coagulase-negative staphylococci and only 
some of them transfer to S. aureus (Grundmann et al., 2006; Ito et al., 2004). It would be interesting 
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to know whether the coagulase-negative staphylococci of the patients possessed the same SCCmec
type V. 
6.3 Laboratory diagnostics of MRSA 
6.3.1 Culturing of S. aureus and MRSA 
In Finland, ORSAB medium was used in more than half of laboratories in screening for MRSA 
directly from the routine clinical samples in 2001. ORSAB was used as a selective medium in both 
of the LTF studies carried out, and the results suggest that the medium was insensitive to the 
isolates expressing low-level oxacillin resistance, and was highly non-specific. ORSAB with 6 mg/l 
oxacillin, as CLSI recommends for screening, proved to be a valuable method for MDR, but may 
miss part of NMDR MRSA (Merlino et al., 2002b). According to the same study, if the oxacillin 
concentration is lowered to 2 mg/l, the ORSAB medium will also give a good correlation with 
NMDR (Merlino et al., 2002b). However, the ORSAB used in both of the present studies contained 
only 2 mg/l of oxacillin. Poor growth may be due to a very low amount of MRSA in specimens, or 
to inhibition by the high salt concentration (Van Enk and Thompson, 1992). In addition, almost one 
third of screening specimens obtained from NH in the Helsinki metropolitan area grew in ORSAB, 
which developed blue colonies, but only 1% of those were MRSA. Half of those blue-colony-
growing bacteria were isolated from perineal swabs, and nearly all comprised coagulase-negative 
staphylococci (data not shown). The specificity of ORSAB decreased after 24 h of incubation, but 
to detect as well the MRSA strains that express very low-level oxacillin resistance, it is advisable to 
incubate the plate for as long as 96 h. Others have also reported problems with the specificity of 
ORSAB (Becker et al., 2002; Blanc et al., 2003). The percentages of sensitivity (60-67%) and 
specificity (study IV: 93% after 24 h, and 72% after 96h, respectively) obtained in these studies are 
low, but the results are likely to be a bit misleading than those of other works, because only three 
MRSA were found in study IV, and five MRSA in study III. Other commercial MRSA-selective 
media have been introduced recently, and have proven to perform with relatively good sensitivity 
and specificity (Compernolle et al., 2007; Flayhart et al., 2005; Louie et al., 2006; Loulergue et al., 
2006; Pape et al., 2006; Perry et al., 2004; Stoakes et al., 2006), even with perineal swabs (Perry et 
al., 2004).  
An additional 5% of S. aureus isolates were detected with enrichment broth in the study IV. This is 
less than that reported in other studies (Blanc et al., 2003; Safdar et al., 2003; van Ogtrop, 1995). 
However, one of the three MRSA isolates would have been missed without enrichment broth. Since 
only 0.6% of S. aureus isolates were found in a primary culture, it may be suggested that a primary 
culture is not necessary if a proper enrichment culture will be done. In this study, using enrichment 
broth was most effective in finding skin lesion isolates, followed by perineum isolates. Some of the 
screening sites were highly colonized with gram-negative rods, especially the perineal swabs with 
the swarming Proteus species (data not shown). Being aware of this problem, CLED agar was used 
in primary culturing or subculturing. The addition of antimicrobials, such as azreonam or nalidixic 
acid, to the broth would also have prevented this contaminating growth. A limitation of the study III 
was that S. aureus was screened without enrichment broth. Several studies have reported that one 
cannot avoid the use of an enrichment broth without a loss of sensitivity in the MRSA screening 
(Blanc et al., 2003; Safdar et al., 2003; van Ogtrop, 1995), although contradictory results do exist 
(VandenBergh et al., 1999). 
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6.3.2 Phenotypic detection of methicillin resistance in S. aureus 
There was a wide variation in the MRSA screening practises used in Finnish microbiology 
laboratories, and especially the incubation times and incubation temperatures, vary widly and were 
not uniform. This may cause problems, especially in the detection of oxacillin-resistant-only 
isolates, heterogeneously resistant isolates, and isolates expressing low-level oxacillin MICs. The 
oxacillin disk diffusion test may miss part of the MRSA strains if the incubation time is not 24 h, as 
guided by CLSI recommends. The recommended incubation temperature for the oxacillin test is 
35°C, but some of the heterogeneously resistant isolates are thermosensitive, and changing the 
temperature to 30°C may sometimes result in a large proportion of cells appearing resistant (Brown 
and Kothari, 1974; Merlino et al., 2002b). In the study V for evaluating phenotypic methods, 
decreasing the temperature failed to increase the sensitivity. On the contrary, sensitivity decreased, 
especially with cefoxitin. The cefoxitin disk would have missed a total of eight isolates out of 150, 
all of which were incubated at +30°C, and four of those with the salt addition. The performance of 
cefoxitin was, however, better than both oxacillin disk diffusion, and the oxacillin E-test, which 
proved to be the most non-specific. Other studies have evaluated the cefoxitin (Cauwelier et al., 
2004; Felten et al., 2002; Skov et al., 2003; Skov et al., 2006; Swenson and Tenover, 2005) and 
moxalactam (Felten et al., 2002) disk diffusion tests in both MH and Iso-Sensitest agar, and 
reported better performance than that of the oxacillin disk. Two studies (Cauwelier et al., 2004; 
Felten et al., 2002) demonstrated the advantage of using an incubation temperature of 30°C with 
cefoxitin disk diffusion test, whereas a recently published study (Skov et al., 2006) showed no 
advantage to changing the temperature. The amount of salt added to the agar base varied from 0% 
to 5% in Finnish microbiology laboratories. Studies have reported that the addition of up to 5% 
NaCl to the test media improves the detection of resistance (Brown and Yates, 1986; Milne et al., 
1993; Milne et al., 1987), but some strains are adversely affected by NaCl (Brown and Yates, 1986; 
Bruins et al., 2007). As recommended by the CLSI, 2% NaCl supplement in MH agar was used 
which, in the present material, seemed to improve the detection of mecA resistance only with the 
sensitivity of oxacillin E-test. All of the missed MRSA strains belonged to internationally known 
MRSA clones that are known to express oxacillin resistance very heterogeneously. In addition, half 
of the Finnish clinical microbiology laboratories used the latex agglutination test to detect the 
PBP2a protein. In general, this test is very sensitive and specific to S. aureus (Brown and Walpole, 
2001; Cavassini et al., 1999; Sakoulas et al., 2001; Swenson et al., 2001; van Griethuysen et al., 
1999), although it may prove unreliable for colonies grown on a medium containing NaCl (Brown 
and Walpole, 2001) or may require a longer agglutination period than what the manufacturer 
recommends (Swenson et al., 2001).  
6.3.3 Genotypic verification of MRSA 
Only one clinical laboratory in Finland used a PCR test to verify oxacillin-resistance in 2001. The 
sensitivity and specificity of phenotypic methods do not compare with genotypic methods, and thus 
the genotypic methods remain the gold standard for confirming MRSA. Since the KTL concluded 
in 2005 the verification of MRSA as a routine method and focused on molecular typing, the number 
of laboratories using molecular techniques has risen. In addition, such commercial diagnostic tests 
have increasingly come to the market, thus making verification easier. Due to this, a total of 12 
clinical microbiology laboratories were using some sort of molecular application for verification of 
MRSA in 2006 (Anni Virolainen-Julkunen, personal communication). Two commercial molecular-
based methods were tested for verifying MRSA and they were compared to two in-house PCR 
methods. 
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GenoType® MRSA and EVIGENETM MRSA Detection tests were found over twice as fast and 
simpler than in-house PCR systems; thus these methods are suitable for confirming MRSA 
routinely in clinical microbiology laboratories. Cuny and colleagues have reported 100% sensitive 
and specific results for detecting MRSA in comparison to in-house mecA-nuc PCR with the former 
version of the GenoType® MRSA test (Cuny et al., 2001). However, many coagulase negative 
staphylococcal species, especially Staphylococcus epidermidis, possess the mecA gene (Petinaki et 
al., 2001), which may confuse the detection of MRSA. The improvement on the present version of 
GenoType® MRSA is the addition of a gene probe specific to Staphylococcus epidermidis. The 
GenoType® MRSA test correctly identified all the examined strains of Staphylococcus epidermidis 
(and mecA gene, if present), and no cross-reactions with other staphylococcal species were detected. 
Skov and colleagues have also reported that their results with the EVIGENETM MRSA Detection 
test were in total agreement with the results obtained by both Southern blot and PCR methods (Skov 
et al., 1999).  
Microbiological testing is still based largely on culturing, but rapid commercial tests directly from 
specimens have become available. These tests are promising (de San et al., 2007; Desjardins et al., 
2006; Francois et al., 2007; Holfelder et al., 2006; Huletsky et al., 2005; van Hal et al., 2007; 
Warren et al., 2004), although, as presented recently, their clinical quality performance is yet far 
from optimal (van Belkum et al., 2007). In addition, some of them have been reported to miss 
MRSA strains possessing new SCCmec types or non-typeable strains (Francois et al., 2007), and 
therefore should be developed to identify the new SCCmec types as well.   
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7. CONCLUSIONS 
The key findings in this present study are: 
I. The rates of MRSA and screening practices varied widely across geographic regions. NMDR 
MRSA isolates, especially those resistant only to oxacillin/methicillin, showed an emerging trend. 
Part of these MRSA strains could remain undetected in some laboratories because of current 
diagnostic techniques used. The increasing proportion of elderly population carrying MRSA 
suggests that MRSA is an emerging problem in Finnish long-term facilities. 
II. The trend in MRSA incidence was rising and the predominant MRSA strains changed over time 
and place, but two internationally spread epidemic strains of MRSA, FIN-16 and FIN-21, were 
related to the rise detected most recently. Those strains were also one cause of the striking increase 
in the number of invasive MRSA findings, thus showing the real worsening situation in Finland. 
The most common strains found from clinical specimens of the patients were the FIN-16 and FIN-4 
strains, and from the screening specimens, FIN-7. The rise of MRSA strains with SCCmec types IV 
or V, possible CA-MRSA, was also detected. 
III. The original MRSA outbreak in LTF, which consisted of isolates possessing a nationally new 
PFGE profile (FIN-22) and internationally rare MLST type (ST-27), was confined. Another 
previously unrecognized MRSA strain was found with additional screening, possibly indicating that 
current routine MRSA screening methods may be insufficiently sensitive for strains possessing low-
level oxacillin resistance. Most of the MSSA strains found were genotypically related to the 
epidemic MRSA strains, but only a few of them had received the SCCmec element, and all those 
strains possessed the new SCCmec type V.  
IV. Combining the use of enrichment broth and perineal swabbing, in addition to swabbing nostrils 
and skin lesions, could be an alternative to throat swabs in nursing home settings, especially when 
residents are uncooperative.  
V. The cefoxitin disk diffusion method is superior to the oxacillin disk diffusion and MIC tests in 
predicting mecA-mediated resistance in S. aureus when incubating at +35°C. Both the Geno Type®
MRSA and EVIGENETM MRSA tests are usable, accurate, cost-effective, and sufficiently fast 
methods for rapid MRSA confirmation from a pure culture. 
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8. FUTURE CONSIDERATIONS 
The future probably holds the never-ending battle with smirking S. aureus. In recent years, MRSA 
clones have emerged that are particularly fit for survival and spread beyond health care settings. In 
contrast to HA-MRSA clones, these CA-MRSA clones are often resistant only to beta-lactam 
antibiotics and may express resistance heterogeneously. Consequently, clinical microbiology 
laboratories may find it very challenging to detect these strains. According to our study, the 
proposed prevalence of CA-MRSA increased in Finland, although two internationally recognized 
hospital-acquired MRSA strain types were mainly responsible for the recent but geographically-
restricted rise in MRSA rates. This new epidemiological situation with a community-associated 
MRSA strain is occurring worldwide, and should be studied more extensively in Finland. In 
addition, studying the virulence genes of strains that have caused severe infections would provide 
more information on the pathogenesis of MRSA strains circulating in Finland. Furthermore, 
sporadic strains have been reported to associate more often with community acquisition than with 
hospital acquisition, and it certainly may prove interesting to characterize these strains with greater 
specificity than that provided by mere typing with PFGE. Further studies are also needed to 
discover why some MSSA strains integrate mecA while other strains do not, and to investigate the 
SCCmec region of CoNS to get more information about the interspecies transfer of genetic 
information.  
  
Since the elderly population in Finland is increasing, thus placing a greater burden on the healthcare 
system, the number of patients presumably bringing MRSA into hospitals with them will also 
increase. Controlling MRSA in long-term facilities is therefore important, but it faces with special 
challenges because it deals with a setting considered the resident’s own home. It is necessary to 
make major surveillance efforts to detect the extent of the problem, and to introduce measures to 
prevent and control outbreaks in long-term facilities as much as in hospital settings. Politicians and 
healthcare administrators play a key role in providing the necessary resources for the problem. The 
Ministry of Social Affairs and Health in Finland allocated additional funds for MRSA prevention 
for the years 2005-2006; thus far, this special investment may have paid off because the rising 
incidence of new MRSA cases seems to be slowing. The most permanent trends in the near future, 
however, remain to be seen.  
The importance of commercial methods in the identification of MRSA isolates will probably 
increase in the future, and especially that of screening assays to detect MRSA directly from the 
clinical specimens. In addition to two PCR-based methods, and a system that employs 
bioluminescence to detect the adenylate kinase of viable MRSA cells recently described, an 
important area for the application of chip arrays will emerge. Chip arrays, which have been used 
mainly in research setting (Koessler et al., 2006), would likely be developed for the rapid screening 
of bacterial isolates for both identification and antimicrobial resistance gene detection in clinical 
microbiology laboratories. At present, however, using a small chip for only one screening swab to 
detect MRSA may not be cost-effective.  
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